Skip to Content
You are currently on the new version of our website. Access the old version .
  • Review
  • Open Access

17 December 2025

31 Pages

Sarcopenia in the Aging Process: Pathophysiological Mechanisms, Clinical Implications, and Emerging Therapeutic Approaches

,
,
,
,
,
,
,
,
…
1
Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil
2
Department of Gerontology, School of Gerontology, Universidade Federal de São Carlos (UFSCar), São Carlos 13565-905, SP, Brazil
3
Department of Biochemistry and Nutrition, School of Food and Technology of Marília (FATEC), Marília 17500-000, SP, Brazil
4
Graduate Program in Structural and Functional Interactions in Rehabilitation, School of Medicine, Universidade de Marília (UNIMAR), Marília 17525-902, SP, Brazil

Abstract

In the face of population aging, sarcopenia has emerged as a significant muscle disorder characterized by the progressive loss of muscle mass, strength, and function. Chronic inflammation, oxidative stress, and mitochondrial dysfunction contribute to sarcopenia and help explain its association with comorbidities such as type 2 diabetes, obesity, and neurodegenerative diseases. Despite extensive research, there remains a need to integrate current knowledge on interventions that target these interconnected mechanisms. This review synthesizes recent evidence on the effects of resistance exercise, nutritional supplementation (high-protein intake, leucine, vitamin D, omega-3 fatty acids), and probiotic use on muscle function and inflammatory status in older adults with sarcopenia. Literature was critically analyzed to evaluate the efficacy of multicomponent strategies. The reviewed studies consistently report that combining resistance training with anti-inflammatory nutrition and targeted supplementation improves muscle strength, reduces pro-inflammatory cytokines, and supports mitochondrial function. These findings suggest that an integrated, multicomponent approach represents a promising strategy for attenuating the progression of sarcopenia and reducing its associated comorbidities.

1. Introduction

Sarcopenia is defined, according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) study, as a muscle disorder characterized by progressive and generalized loss of the quality and quantity of skeletal muscle structure [1], resulting in adverse events such as difficulty in locomotion [2] and, in extreme cases, mortality [3]. Studies show that sarcopenia currently has a prevalence of 8% to 36% in individuals under 60 years of age and 10% to 27% in those over 60 years old, demonstrating an escalating trend in terms of prevalence annually [4].
Because sarcopenia is fundamentally an age-related condition, understanding how aging alters muscle homeostasis is essential to clarifying its mechanisms. Aging acts as the biological backdrop against which these structural and metabolic changes occur. Aging disrupts the balance between anabolic and catabolic pathways, leading to structural changes such as reduced type II fiber size and number, increased fat infiltration, and fewer satellite cells, which are responsible for replacing and repairing damaged muscle fibers [5,6,7]. This decline is attributable to alterations in systemic signaling pathways, including the transforming growth factor beta (TGF-β) and myogenin, which regulate satellite cell differentiation and activation. Other factors contributing to these changes include neuromuscular junction dysfunction, loss of motor units, chronic inflammation, and insulin resistance [8,9,10,11,12].
Sarcopenia also directly reduces the quality of life because it is closely linked to chronic conditions such as type 2 diabetes mellitus (T2DM) and obesity. A large part of the population is vulnerable to sarcopenia at some point in their lives [13,14]. Patients who may develop sarcopenia include the elderly, underweight people, and people with other chronic conditions. Moreover, individuals with T2DM are more likely to be affected by this condition, as it can aggravate metabolic disorders and compromise response to treatments [15,16,17].
Sarcopenia develops from various etiologies and can be characterized as primary or secondary. Primary sarcopenia is primarily associated with age, while secondary sarcopenia is influenced by risk factors related to muscle loss, such as sarcopenic obesity, cancer, malnutrition, and rheumatic diseases [18,19]. It is also essential to highlight the risk factors for primary sarcopenia as contributors to secondary sarcopenia, as a sedentary lifestyle and physical inactivity are triggers of this condition, even in early life [20].
These combined factors show that aging not only drives sarcopenia but also contributes to a broader systemic deterioration, affecting various physiological systems beyond skeletal muscle. This connection establishes a biological continuum between muscle aging and broader degenerative processes. Thus, hormonal changes associated with aging were observed to trigger muscle loss, with androgens playing a crucial role in maintaining cellular metabolic activity by suppressing catabolic processes and exerting an anti-inflammatory effect on peripheral tissues [21]. Therefore, low testosterone levels are associated with the pathophysiology and progression of age-related diseases, such as sarcopenia, thus establishing hormone replacement therapy as a pillar in the treatment of different pathologies [22,23,24].
Increasing evidence suggests that the mechanisms leading to muscle atrophy in sarcopenia—such as chronic inflammation, mitochondrial dysfunction, and hormonal imbalance—are also implicated in neurodegenerative processes. Thus, the muscle-brain axis has emerged as a critical focus in geroscience, linking functional decline to cognitive decline. On the other hand, it is known that advanced aging is still a crucial factor in the development of dementia, which is directly associated with disability and mortality [4,25]. Other factors, such as genetic, socioeconomic, and environmental factors, as well as physical activity and a balanced diet, are key determinants of cognitive impairment [26,27]. Geroscience offers molecular explanations for the pathophysiology of sarcopenia, frailty, and cognitive decline, encompassing several age-related processes. Studies show that muscle mass can serve as a tunable biomarker in dementia prevention. In other words, neurodegenerative changes tend to emerge with advancing age and are linked to the progressive and widespread loss of skeletal muscle, known as sarcopenia [28,29,30]. Parkinson’s disease (PD), a movement disorder characterized by the death of dopaminergic neurons, is also shown to be a change related to muscle impairment [31]. Thus, studies show the prevalence of sarcopenia in more than 50% of those affected by PD, which is associated with worse progression, greater motor impairment, and high frequency of falls, in addition to affecting non-motor symptom outcomes [32,33,34].
Sarcopenia and neurodegenerative diseases currently represent a significant socioeconomic challenge, generating high healthcare costs and a loss of functional independence and productivity, significantly reducing quality of life. Furthermore, they overload public healthcare systems, thus widening social inequalities.
Because these mechanisms overlap, studying sarcopenia and neurodegeneration together becomes essential, as understanding one can illuminate aspects of the other. Therefore, this review seeks to comprehensively review the intersection between sarcopenia and neurodegenerative diseases, considering aging, muscle loss, and cognitive decline. The detailed methodology employed for this review is presented in Appendix A.

3. Conclusions

Given the numerous mechanisms that contribute to sarcopenia in aging, further research is needed to elucidate its underlying mechanisms and pathological processes, and to identify effective treatments and preventive measures for clinical practice. Several pathophysiological mechanisms can cause sarcopenia. Despite the inconclusive findings, its association with inflammatory pathways, mitochondrial dysfunction, and oxidative stress is evident. Elevated levels of inflammatory cytokines, such as IL-6, TNF-α, and CRP, were also observed in comorbidities related to the development of sarcopenia, such as T2DM, obesity, mitochondrial dysfunction, and metabolic alterations, confirming the current state of occurrence in the scenario evaluated, in addition to establishing common pathways for its pathological origin. Thus, unique comorbidities, such as T2DM and AD, were shown to be associated, underscoring the need to consider shared pathological biomarkers. Furthermore, the gut–brain–muscle axis was evaluated for its influence on skeletal muscle, revealing a low-grade inflammatory state and anabolic resistance, driven by changes in the gut microbiota composition. Consequently, physical and nutritional interventions, such as the Mediterranean diet, have been shown to positively impact the intestinal environment, highlighting the need for further studies on specific probiotics and microbiota-modulating diets to establish their effectiveness in clinical practice. Furthermore, studies demonstrate the prevention of sarcopenia through regular exercise and a healthy diet. Regarding the treatment of the evaluated condition, exposure to leucine alone or in combination with vitamin D and whey protein is significantly adequate. However, clinical guidelines and therapeutic plans remain inconclusive in the medical community. Finally, promising strategies for addressing the prospects of sarcopenia include amino acid supplementation, such as leucine, omega-3 fatty acids, and the probiotic Lactobacillus, as well as the monoclonal antibody Bimagrumab®, which has demonstrated effects in reducing muscle loss through various mechanisms.
While this review provides a comprehensive synthesis of current literature on the interactions among gut microbiota, sarcopenia, and cognition, several limitations should be acknowledged. First, our study is a narrative review rather than a formal meta-analysis, and we did not conduct a systematic critical appraisal of study quality, which may influence the robustness of the conclusions. Second, the selection of included studies may be subject to publication bias, as negative or null findings are less likely to be published. Third, much of the existing literature is derived from Western populations, which may limit the generalizability of our findings to other ethnic or geographical groups. Finally, many mechanistic pathways discussed remain based on preclinical or associative data, highlighting the need for further experimental and longitudinal human studies to confirm causal relationships. Despite these limitations, we believe that this review provides a valuable framework for understanding the gut–muscle–brain axis and identifies key avenues for future research.

4. Future Perspectives

Given the relevance of sarcopenia and its multisystemic effects, such as cognitive decline, it is necessary to perform more studies aiming to clearly and directly demonstrate the mechanisms by which the onset of sarcopenia influences the development of various pathologies, including neurodegenerative diseases. These are also influenced by population aging itself and the most common pathologies in the elderly, such as T2DM and even obesity, all pathways linking sarcopenia to adverse health outcomes, particularly in populations with comorbidities such as cardiovascular disease, metabolic disorders, and chronic inflammation. Longitudinal studies with larger and more diverse cohorts are needed to establish predictive biomarkers and validate diagnostic criteria across different age groups and ethnicities. Furthermore, integrating multiomics approaches (genomics, proteomics, metabolomics) with advanced imaging techniques can provide deeper insights into muscle metabolism and its systemic interactions. The development and validation of targeted interventions combining nutritional strategies, physical activity protocols, and pharmacological agents should be prioritized, with a focus on individualized, precision-based medicine. Ultimately, collaborative, multidisciplinary efforts will be essential to translate mechanistic discoveries into effective public health strategies for the prevention and treatment of sarcopenia.

Author Contributions

Conceptualization, L.P.A., A.C.F.G., F.F.F. and S.M.B.; investigation, L.P.A., A.C.F.G., F.F.F. and S.M.B.; writing—original draft preparation, L.P.A., A.C.F.G., F.F.F., C.B.L., K.Q., C.R.P.D., A.C.A., M.A.M., E.L.G., R.S.d.A.H., E.d.S.B.M.P., V.C.S.C. (Virgínia Cavallari Strozze Catharin), V.C.S.C. (Vitor Cavallari Strozze Catharin), L.F.L. and S.M.B.; writing—review and editing, L.P.A., A.C.F.G., F.F.F., C.B.L., K.Q., C.R.P.D., A.C.A., M.A.M., E.L.G., R.S.d.A.H., E.d.S.B.M.P., V.C.S.C. (Virgínia Cavallari Strozze Catharin), V.C.S.C. (Vitor Cavallari Strozze Catharin), L.F.L. and S.M.B.; visualization, L.P.A., A.C.F.G., F.F.F. and S.M.B.; supervision, S.M.B.; project administration, S.M.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing does not apply to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Appendix A

  • Study Design
This work was conducted as an integrative literature review to synthesize recent evidence on the cellular mechanisms, clinical associations, and therapeutic strategies related to sarcopenia and its risk factors.
  • Search Strategy
A comprehensive search was conducted in the PubMed, Scopus, Web of Science, and ScienceDirect databases for relevant studies. We did not restrict the search period. Additional sources were identified through Google Scholar and manual review of references. The search combined terms such as “sarcopenia,” “muscle atrophy,” “oxidative stress,” “inflammation,” “mitochondrial dysfunction,” “aging,” “diabetes,” “obesity,” “neurodegeneration,” “microbiota,” “therapy,” “exercise,” and “nutrition.”
  • Eligibility Criteria
Studies were included if they examined sarcopenia or muscle atrophy in adult or elderly populations and explored molecular, cellular, or clinical mechanisms, or evaluated preventive and therapeutic interventions. Case reports, abstracts, and non-peer-reviewed sources were excluded.
  • Data Extraction and Synthesis
Data were extracted and organized into thematic domains: (1) cellular and molecular mechanisms, (2) associated clinical conditions, (3) gut–muscle–brain interactions, and (4) therapeutic strategies. Figures were prepared using BioRender (https://BioRender.com, last accessed on 3 December 2025).

References

  1. Mao, X.; Lv, K.; Qi, W.; Cheng, W.; Li, T.; Sun, Y.; Jin, H.; Pan, H.; Wang, D. Research progress on sarcopenia in the musculoskeletal system. Bone Res. 2025, 13, 78. [Google Scholar] [CrossRef] [Scilit]
  2. Jung, H.; Tanaka, S.; Kataoka, S.; Tanaka, R. Association of sarcopenia, pre-sarcopenia, and dynapenia with the onset and progression of locomotive syndrome in Japanese older adults: A cross-sectional study. J. Physiol. Anthropol. 2023, 42, 16. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Liu, J.; Zhang, F. Associations between sarcopenia (defined by low muscle mass), inflammatory markers, and all-cause mortality in older adults: Mediation analyses in a large U.S. NHANES community sample, 1999–2006. Front. Med. 2025, 12, 1515839. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Huang, J.; Li, M.; Luo, Q.; Li, J. The association of sarcopenia, possible sarcopenia and cognitive impairment: A systematic review and meta-analysis. PLoS ONE 2025, 20, e0324258. [Google Scholar] [CrossRef] [Scilit]
  5. Wang, T.; Zhou, D.; Hong, Z. Sarcopenia and cachexia: Molecular mechanisms and therapeutic interventions. MedComm 2025, 6, e70030. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  6. Alorfi, N.M.; Alshehri, F.S.; Ashour, A.M. Therapeutics for Sarcopenia and Functional Disabilities in Older Adults: A Review of Phase 4 Clinical Trials. Drug Des. Dev. Ther. 2025, 19, 2307–2314. [Google Scholar] [CrossRef] [Scilit]
  7. Laurindo, L.F.; Rodrigues, V.D.; Laurindo, L.F.; Cherain, L.M.A.; de Lima, E.P.; Boaro, B.L.; da Silva Camarinha Oliveira, J.; Chagas, E.F.B.; Catharin, V.C.S.; Dos Santos Haber, J.F.; et al. Targeting AMPK with Irisin: Implications for metabolic disorders, cardiovascular health, and inflammatory conditions—A systematic review. Life Sci. 2025, 360, 123230. [Google Scholar] [CrossRef] [Scilit]
  8. Nunes-Pinto, M.; Bandeira de Mello, R.G.; Pinto, M.N.; Moro, C.; Vellas, B.; Martinez, L.O.; Rolland, Y.; de Souto Barreto, P. Sarcopenia and the biological determinants of aging: A narrative review from a geroscience perspective. Ageing Res. Rev. 2025, 103, 102587. [Google Scholar] [CrossRef] [Scilit]
  9. Wang, N.; Zheng, A.; Yan, Y.; He, T.; Wu, X.; Xian, M.; Luo, J.; Li, C.; Wei, J.; Wang, Y.; et al. Aging induces sarcopenia by disrupting the crosstalk between the skeletal muscle microenvironment and myofibers. J. Adv. Res. 2025. [Google Scholar] [CrossRef] [Scilit]
  10. Ceccarelli Ceccarelli, D.; Solerte, S.B. Unravelling Shared Pathways Linking Metabolic Syndrome, Mild Cognitive Impairment, Dementia, and Sarcopenia. Metabolites 2025, 15, 159. [Google Scholar] [CrossRef] [Scilit]
  11. Burks, T.N.; Cohn, R.D. Role of TGF-β signaling in inherited and acquired myopathies. Skelet. Muscle 2011, 1, 19. [Google Scholar] [CrossRef] [Scilit]
  12. Shirakawa, T.; Toyono, T.; Inoue, A.; Matsubara, T.; Kawamoto, T.; Kokabu, S. Factors Regulating or Regulated by Myogenic Regulatory Factors in Skeletal Muscle Stem Cells. Cells 2022, 11, 1493. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Habboub, B.; Speer, R.; Gosch, M.; Singler, K. The Diagnosis and Treatment of Sarcopenia and Sarcopenic Obesity. Dtsch. Arztebl. Int. 2025, 122, 121–126. [Google Scholar] [CrossRef] [Scilit]
  14. Yogesh, M.; Patel, M.; Gandhi, R.; Patel, A.; Kidecha, K.N. Sarcopenia in type 2 Diabetes mellitus among Asian populations: Prevalence and risk factors based on AWGS- 2019: A systematic review and meta-analysis. BMC Endocr. Disord. 2025, 25, 101. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Xie, R.Z.; Li, X.S.; Zha, F.D.; Li, G.Q.; Zhao, W.Q.; Liang, Y.F.; Huang, J.F. Relationship Between Body Mass Index and Low Skeletal Muscle Mass in Adults Based on NHANES 2011–2018. Sci. Rep. 2025, 15, 2596. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Aguiar, M.B.; Kim, S.; Bortoluzzo, A.B.; Di Tommaso, A.B.; Cendoroglo, M.S.; Colleoni, G.W.B. Sarcopenia in independent oldest-old individuals treated for diabetes, with or without metformin: A case-control study. Acta Diabetol. 2025, 62, 1271–1281. [Google Scholar] [CrossRef] [Scilit]
  17. Wang, X.; Bai, Y.; Zhang, F.; Que, H. Association of sarcopenia index, based on serum creatinine and cystatin C, with incident diabetes mellitus. Eur. J. Med. Res. 2025, 30, 151. [Google Scholar] [CrossRef] [Scilit]
  18. Elnaggar, R.K.; Mahmoud, W.S.; Abdrabo, M.S.; Elfakharany, M.S. Effect of adaptive variable-resistance training on chemotherapy-induced sarcopenia, fatigue, and functional restriction in pediatric survivors of acute lymphoblastic leukemia: A prospective randomized controlled trial. Support. Care Cancer 2025, 33, 214. [Google Scholar] [CrossRef] [Scilit]
  19. Lee, M.C.; Hsu, Y.J.; Yang, H.J.; Huang, C.C. Enhancement of Lower Limb Muscle Strength and Reduction of Inflammation in the Elderly: A Randomized, Double-Blind Clinical Trial Comparing. Nutrients 2025, 17, 463. [Google Scholar] [CrossRef] [Scilit]
  20. Hämäläinen, O.O.; Savikangas, T.M.; Tirkkonen, A.K.; Alén, M.J.; Hautala, A.J.; Sipilä, S. Effects of 12-month physical and cognitive training on sarcopenia determinants in older adults: A subgroup analysis of a randomised clinical trial. Aging Clin. Exp. Res. 2025, 37, 36. [Google Scholar] [CrossRef] [Scilit]
  21. Urban, R.J.; Dillon, E.L.; Choudhary, S.; Zhao, Y.; Horstman, A.M.; Tilton, R.G.; Sheffield-Moore, M. Translational studies in older men using testosterone to treat sarcopenia. Trans. Am. Clin. Climatol. Assoc. 2014, 125, 27–42; discussion 42–44. [Google Scholar]
  22. Atkinson, R.A.; Srinivas-Shankar, U.; Roberts, S.A.; Connolly, M.J.; Adams, J.E.; Oldham, J.A.; Wu, F.C.; Seynnes, O.R.; Stewart, C.E.; Maganaris, C.N.; et al. Effects of testosterone on skeletal muscle architecture in intermediate-frail and frail elderly men. J. Gerontol. A Biol. Sci. Med. Sci. 2010, 65, 1215–1219. [Google Scholar] [CrossRef] [Scilit]
  23. O’Connell, M.D.; Ravindrarajah, R.; Tajar, A.; Wu, F.C. Low testosterone in ageing men: A modifiable risk factor for frailty? Trends Endocrinol. Metab. 2011, 22, 491–498. [Google Scholar] [CrossRef] [Scilit]
  24. Wittert, G.A.; Chapman, I.M.; Haren, M.T.; Mackintosh, S.; Coates, P.; Morley, J.E. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J. Gerontol. A Biol. Sci. Med. Sci. 2003, 58, 618–625. [Google Scholar] [CrossRef] [Scilit]
  25. Sha, T.; Zhang, Y.; Wei, J.; Li, C.; Zeng, C.; Lei, G.; Wang, Y. Sarcopenia and Risk of Cognitive Impairment: Cohort Study and Mendelian Randomization Analysis. JMIR Aging 2025, 8, e66031. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Moradell, A.; Casajús, J.A.; Moreno, L.A.; Vicente-Rodríguez, G. Perspectives on Diet and Exercise Interaction for Healthy Aging: Opportunities to Reduce Malnutrition Risk and Optimize Fitness. Nutrients 2025, 17, 596. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. German, I.J.S.; Pomini, K.T.; Andreo, J.C.; Shindo, J.; Castro, M.V.M.; Detregiachi, C.R.P.; Araújo, A.C.; Guiguer, E.L.; Fornari Laurindo, L.; Bueno, P.; et al. New Trends to Treat Muscular Atrophy: A Systematic Review of Epicatechin. Nutrients 2024, 16, 326. [Google Scholar] [CrossRef] [Scilit]
  28. Lipoeto, N.I.; Vanoh, D.; Desmawati, D.; Ishak, W.R.W.; Mohamed, R. Determinants of dementia risk among older adults with probable sarcopenia and sarcopenia. BMC Public Health 2025, 25, 1139. [Google Scholar] [CrossRef] [Scilit]
  29. Zhan, Y.; Zhang, Z.; Lin, S.; Du, B.; Zhang, K.; Wu, J.; Xu, H. Causal association of sarcopenia-related traits with brain cortical structure: A bidirectional Mendelian randomization study. Aging Clin. Exp. Res. 2025, 37, 57. [Google Scholar] [CrossRef] [Scilit]
  30. Shi, Y.; Zhang, Y.; Yang, X.; Yang, J.; Wang, S.; Hong, Y. The relationship between cognitive function and muscle mass in older adults: A longitudinal study based on CLHLS. Front. Psychiatry 2025, 16, 1595625. [Google Scholar] [CrossRef] [Scilit]
  31. Wang, T.; Geng, J.; Zeng, X.; Han, R.; Huh, Y.E.; Peng, J. Exploring causal effects of sarcopenia on risk and progression of Parkinson disease by Mendelian randomization. npj Park. Dis. 2024, 10, 164. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Peball, M.; Mahlknecht, P.; Werkmann, M.; Marini, K.; Murr, F.; Herzmann, H.; Stockner, H.; de Marzi, R.; Heim, B.; Djamshidian, A.; et al. Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson’s Disease: A Cross-Sectional Study. Gerontology 2019, 65, 216–228. [Google Scholar] [CrossRef] [Scilit]
  33. Tan, A.H.; Hew, Y.C.; Lim, S.Y.; Ramli, N.M.; Kamaruzzaman, S.B.; Tan, M.P.; Grossmann, M.; Ang, B.H.; Tan, J.Y.; Manap, M.A.A.A.; et al. Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson’s disease. Park. Relat. Disord. 2018, 56, 58–64. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Ozer, F.F.; Akın, S.; Gultekin, M.; Zararsız, G.E. Sarcopenia, dynapenia, and body composition in Parkinson’s disease: Are they good predictors of disability? A case-control study. Neurol. Sci. 2020, 41, 313–320. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. de Lima, E.P.; Tanaka, M.; Lamas, C.B.; Quesada, K.; Detregiachi, C.R.P.; Araújo, A.C.; Guiguer, E.L.; Catharin, V.; de Castro, M.V.M.; Junior, E.B.; et al. Vascular Impairment, Muscle Atrophy, and Cognitive Decline: Critical Age-Related Conditions. Biomedicines 2024, 12, 2096. [Google Scholar] [CrossRef] [Scilit]
  36. Zeng, Q.Y.; Qin, Y.; Shi, Y.; Mu, X.Y.; Huang, S.J.; Yang, Y.H.; Liu, S.M.; An, Z.M.; Li, S.Q. Systemic immune-inflammation index and all-cause and cause-specific mortality in sarcopenia: A study from National Health and Nutrition Examination Survey 1999–2018. Front. Immunol. 2024, 15, 1376544. [Google Scholar] [CrossRef] [Scilit]
  37. Xu, W.; Mu, D.; Wang, Y.; Wang, C.; Zhang, X. Association between oxidative balance score and sarcopenia in US adults: NHANES 2011–2018. Front. Nutr. 2024, 11, 1342113. [Google Scholar] [CrossRef] [Scilit]
  38. Hernández-Álvarez, D.; Rosado-Pérez, J.; Gavia-García, G.; Arista-Ugalde, T.L.; Aguiñiga-Sánchez, I.; Santiago-Osorio, E.; Mendoza-Núñez, V.M. Aging, Physical Exercise, Telomeres, and Sarcopenia: A Narrative Review. Biomedicines 2023, 11, 598. [Google Scholar] [CrossRef] [Scilit]
  39. Chen, M.; Wang, Y.; Deng, S.; Lian, Z.; Yu, K. Skeletal muscle oxidative stress and inflammation in aging: Focus on antioxidant and anti-inflammatory therapy. Front. Cell Dev. Biol. 2022, 10, 964130. [Google Scholar] [CrossRef] [Scilit]
  40. Franceschi, C.; Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69, S4–S9. [Google Scholar] [CrossRef] [Scilit]
  41. Zembron-Lacny, A.; Dziubek, W.; Wolny-Rokicka, E.; Dabrowska, G.; Wozniewski, M. The Relation of Inflammaging with Skeletal Muscle Properties in Elderly Men. Am. J. Mens Health 2019, 13, 1557988319841934. [Google Scholar] [CrossRef] [Scilit]
  42. Li, X.; Wu, C.; Lu, X.; Wang, L. Predictive models of sarcopenia based on inflammation and pyroptosis-related genes. Front. Genet. 2024, 15, 1491577. [Google Scholar] [CrossRef] [Scilit]
  43. Beyer, I.; Mets, T.; Bautmans, I. Chronic low-grade inflammation and age-related sarcopenia. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15, 12–22. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  44. Fielding, R.A.; Rolland, Y.; Bruyere, O.; Desvarieux, M.; Donini, L.M.; Incalzi, R.A.; Muscaritoli, M.; Tchalla, A.; Bonnefoy, M.; Rondanelli, M.; et al. Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: A multicenter observational trial (SARA-OBS). BMC Geriatr. 2025, 25, 590. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  45. Laurindo, L.F.; Lima, E.P.; Araújo, A.C.; Dogani Rodrigues, V.; Dias, J.A.; Barbosa Tavares Filho, M.; Zuccari, D.; Fornari Laurindo, L.; Miglino, M.A.; Chagas, E.F.B.; et al. Targeting Muscle Regeneration with Small Extracellular Vesicles from Adipose Tissue-Derived Stem Cells-A Review. Cells 2025, 14, 683. [Google Scholar] [CrossRef] [Scilit]
  46. You, Z.; Huang, X.; Xiang, Y.; Dai, J.; Xu, L.; Jiang, J.; Xu, J. Ablation of NLRP3 inflammasome attenuates muscle atrophy via inhibiting pyroptosis, proteolysis and apoptosis following denervation. Theranostics 2023, 13, 374–390. [Google Scholar] [CrossRef] [Scilit]
  47. Picca, A.; Calvani, R. Molecular Mechanism and Pathogenesis of Sarcopenia: An Overview. Int. J. Mol. Sci. 2021, 22, 3032. [Google Scholar] [CrossRef] [Scilit]
  48. Merchant, R.A.; Chan, Y.H.; Anbarasan, D.; Vellas, B. Association of intrinsic capacity with functional ability, sarcopenia and systemic inflammation in pre-frail older adults. Front. Med. 2024, 11, 1374197. [Google Scholar] [CrossRef] [Scilit]
  49. Arcaro, A.; Lepore, A.; Cetrangolo, G.P.; Paventi, G.; Ames, P.R.J.; Gentile, F. A Reassessment of Sarcopenia from a Redox Perspective as a Basis for Preventive and Therapeutic Interventions. Int. J. Mol. Sci. 2025, 26, 7787. [Google Scholar] [CrossRef] [Scilit]
  50. Dhillon, R.J.; Hasni, S. Pathogenesis and Management of Sarcopenia. Clin. Geriatr. Med. 2017, 33, 17–26. [Google Scholar] [CrossRef] [Scilit]
  51. Xie, S.; Wu, Q. Association between the systemic immune-inflammation index and sarcopenia: A systematic review and meta-analysis. J. Orthop. Surg. Res. 2024, 19, 314. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  52. Guo, B.; Liu, X.; Si, Q.; Zhang, D.; Li, M.; Li, X.; Zhao, Y.; Hu, F.; Zhang, M.; Liu, Y.; et al. Associations of CBC-Derived inflammatory indicators with sarcopenia and mortality in adults: Evidence from Nhanes 1999 ∼ 2006. BMC Geriatr. 2024, 24, 432. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  53. Cleasby, M.E.; Jamieson, P.M.; Atherton, P.J. Insulin resistance and sarcopenia: Mechanistic links between common co-morbidities. J. Endocrinol. 2016, 229, R67–R81. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Damanti, S.; Senini, E.; De Lorenzo, R.; Merolla, A.; Santoro, S.; Festorazzi, C.; Messina, M.; Vitali, G.; Sciorati, C.; Rovere-Querini, P. Acute Sarcopenia: Mechanisms and Management. Nutrients 2024, 16, 3428. [Google Scholar] [CrossRef] [Scilit]
  55. Pascual-Fernández, J.; Fernández-Montero, A.; Córdova-Martínez, A.; Pastor, D.; Martínez-Rodríguez, A.; Roche, E. Sarcopenia: Molecular Pathways and Potential Targets for Intervention. Int. J. Mol. Sci. 2020, 21, 8844. [Google Scholar] [CrossRef] [Scilit]
  56. Khor, S.C.; Abdul Karim, N.; Ngah, W.Z.; Yusof, Y.A.; Makpol, S. Vitamin E in sarcopenia: Current evidences on its role in prevention and treatment. Oxid. Med. Cell. Longev. 2014, 2014, 914853. [Google Scholar] [CrossRef] [Scilit]
  57. Szczesny, B.; Olah, G.; Walker, D.K.; Volpi, E.; Rasmussen, B.B.; Szabo, C.; Mitra, S. Deficiency in repair of the mitochondrial genome sensitizes proliferating myoblasts to oxidative damage. PLoS ONE 2013, 8, e75201. [Google Scholar] [CrossRef] [Scilit]
  58. Barbalho, S.M.; Flato, U.A.P.; Tofano, R.J.; Goulart, R.A.; Guiguer, E.L.; Detregiachi, C.R.P.; Buchaim, D.V.; Araújo, A.C.; Buchaim, R.L.; Reina, F.T.R.; et al. Physical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications. Int. J. Mol. Sci. 2020, 21, 3607. [Google Scholar] [CrossRef] [Scilit]
  59. Bailey, D.M.; McEneny, J.; Mathieu-Costello, O.; Henry, R.R.; James, P.E.; McCord, J.M.; Pietri, S.; Young, I.S.; Richardson, R.S. Sedentary aging increases resting and exercise-induced intramuscular free radical formation. J. Appl. Physiol. 2010, 109, 449–456. [Google Scholar] [CrossRef] [Scilit]
  60. Fanò, G.; Mecocci, P.; Vecchiet, J.; Belia, S.; Fulle, S.; Polidori, M.C.; Felzani, G.; Senin, U.; Vecchiet, L.; Beal, M.F. Age and sex influence on oxidative damage and functional status in human skeletal muscle. J. Muscle Res. Cell Motil. 2001, 22, 345–351. [Google Scholar] [CrossRef] [Scilit]
  61. Fulle, S.; Di Donna, S.; Puglielli, C.; Pietrangelo, T.; Beccafico, S.; Bellomo, R.; Protasi, F.; Fanò, G. Age-dependent imbalance of the antioxidative system in human satellite cells. Exp. Gerontol. 2005, 40, 189–197. [Google Scholar] [CrossRef] [Scilit]
  62. Powers, S.K.; Duarte, J.; Kavazis, A.N.; Talbert, E.E. Reactive oxygen species are signalling molecules for skeletal muscle adaptation. Exp. Physiol. 2010, 95, 1–9. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  63. Marzetti, E.; Calvani, R.; Cesari, M.; Buford, T.W.; Lorenzi, M.; Behnke, B.J.; Leeuwenburgh, C. Mitochondrial dysfunction and sarcopenia of aging: From signaling pathways to clinical trials. Int. J. Biochem. Cell Biol. 2013, 45, 2288–2301. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  64. Hamilton, M.L.; Van Remmen, H.; Drake, J.A.; Yang, H.; Guo, Z.M.; Kewitt, K.; Walter, C.A.; Richardson, A. Does oxidative damage to DNA increase with age? Proc. Natl. Acad. Sci. USA 2001, 98, 10469–10474. [Google Scholar] [CrossRef] [Scilit]
  65. Tian, X.; Lou, S.; Shi, R. From mitochondria to sarcopenia: Role of 17β-estradiol and testosterone. Front. Endocrinol. 2023, 14, 1156583. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  66. Vasilaki, A.; Mansouri, A.; Van Remmen, H.; van der Meulen, J.H.; Larkin, L.; Richardson, A.G.; McArdle, A.; Faulkner, J.A.; Jackson, M.J. Free radical generation by skeletal muscle of adult and old mice: Effect of contractile activity. Aging Cell 2006, 5, 109–117. [Google Scholar] [CrossRef] [Scilit]
  67. Lanza, I.R.; Sreekumaran Nair, K. Regulation of skeletal muscle mitochondrial function: Genes to proteins. Acta Physiol. 2010, 199, 529–547. [Google Scholar] [CrossRef] [Scilit]
  68. Archer, S.L. Mitochondrial dynamics—Mitochondrial fission and fusion in human diseases. N. Engl. J. Med. 2013, 369, 2236–2251. [Google Scholar] [CrossRef] [Scilit]
  69. Wai, T.; Langer, T. Mitochondrial Dynamics and Metabolic Regulation. Trends Endocrinol. Metab. 2016, 27, 105–117. [Google Scholar] [CrossRef] [Scilit]
  70. Hood, D.A.; Memme, J.M.; Oliveira, A.N.; Triolo, M. Maintenance of Skeletal Muscle Mitochondria in Health, Exercise, and Aging. Annu. Rev. Physiol. 2019, 81, 19–41. [Google Scholar] [CrossRef] [Scilit]
  71. Bene, M.R.; Chung, T.; Fountain, W.A.; Rosales-Soto, G.; Hernández-Ochoa, E.; Antonescu, C.; Florea, L.; Jeong, S.J.; Le, A.; Xue, Q.L.; et al. Chronic activation of a key exercise signal transducer, CaMKII, drives skeletal muscle aging and sarcopenia. bioRxiv 2025. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  72. Fan, J.; Wen, X.; Duan, X.; Zhu, X.; Bai, J.; Zhang, T. Mitochondrial quality control in exercise-mitigated muscular atrophy. Mitochondrion 2025, 85, 102074. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  73. Chen, X.; Ji, Y.; Liu, R.; Zhu, X.; Wang, K.; Yang, X.; Liu, B.; Gao, Z.; Huang, Y.; Shen, Y.; et al. Mitochondrial dysfunction: Roles in skeletal muscle atrophy. J. Transl. Med. 2023, 21, 503. [Google Scholar] [CrossRef] [Scilit]
  74. Arosio, B.; Calvani, R.; Ferri, E.; Coelho-Junior, H.J.; Carandina, A.; Campanelli, F.; Ghiglieri, V.; Marzetti, E.; Picca, A. Sarcopenia and Cognitive Decline in Older Adults: Targeting the Muscle-Brain Axis. Nutrients 2023, 15, 1853. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  75. Divino, I.A.; da Vieira-da-Silva, A.L.; Esteca, M.V.; Tonon, R.P.; da Cruz, F.O.G.; Braga, R.R.; Ropelle, E.R.; Gandra, P.G.; Baptista, I.L. Absence of Parkin Results in Atrophy of Oxidative Myofibers and Modulation of AKT and MURF1 Signaling in Middle-Aged Male Mice. Acta Physiol. 2025, 241, e70082. [Google Scholar] [CrossRef] [Scilit]
  76. Mantle, D.; Kozhevnikova, S.; Larsen, S. Coenzyme Q10 and Obesity: An Overview. Antioxidants 2025, 14, 871. [Google Scholar] [CrossRef] [Scilit]
  77. Lei, Y.; Gan, M.; Qiu, Y.; Chen, Q.; Wang, X.; Liao, T.; Zhao, M.; Chen, L.; Zhang, S.; Zhao, Y.; et al. The role of mitochondrial dynamics and mitophagy in skeletal muscle atrophy: From molecular mechanisms to therapeutic insights. Cell. Mol. Biol. Lett. 2024, 29, 59. [Google Scholar] [CrossRef] [Scilit]
  78. Kubat, G.B.; Bouhamida, E.; Ulger, O.; Turkel, I.; Pedriali, G.; Ramaccini, D.; Ekinci, O.; Ozerklig, B.; Atalay, O.; Patergnani, S.; et al. Mitochondrial dysfunction and skeletal muscle atrophy: Causes, mechanisms, and treatment strategies. Mitochondrion 2023, 72, 33–58. [Google Scholar] [CrossRef] [Scilit]
  79. Abrigo, J.; Simon, F.; Cabrera, D.; Vilos, C.; Cabello-Verrugio, C. Mitochondrial Dysfunction in Skeletal Muscle Pathologies. Curr. Protein Pept. Sci. 2019, 20, 536–546. [Google Scholar] [CrossRef] [Scilit]
  80. Faitg, J.; Reynaud, O.; Leduc-Gaudet, J.P.; Gouspillou, G. Skeletal muscle aging and mitochondrial dysfunction: An update. Med. Sci. 2017, 33, 955–962. [Google Scholar] [CrossRef] [Scilit]
  81. Srivastava, S. The Mitochondrial Basis of Aging and Age-Related Disorders. Genes 2017, 8, 398. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  82. Ferri, E.; Marzetti, E.; Calvani, R.; Picca, A.; Cesari, M.; Arosio, B. Role of Age-Related Mitochondrial Dysfunction in Sarcopenia. Int. J. Mol. Sci. 2020, 21, 5236. [Google Scholar] [CrossRef] [Scilit]
  83. Leduc-Gaudet, J.P.; Hussain, S.N.A.; Barreiro, E.; Gouspillou, G. Mitochondrial Dynamics and Mitophagy in Skeletal Muscle Health and Aging. Int. J. Mol. Sci. 2021, 22, 8179. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  84. Ceyhan, A.B.; Altay, O.; Zhang, C.; Temel, S.G.; Turkez, H.; Mardinoglu, A. Unravelling the Complexity of Sarcopenia Through a Systems Biology Approach. Int. J. Mol. Sci. 2025, 26, 8527. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  85. Yang, J.; Jiang, F.; Yang, M.; Chen, Z. Sarcopenia and nervous system disorders. J. Neurol. 2022, 269, 5787–5797. [Google Scholar] [CrossRef] [Scilit]
  86. Huang, Y.; Wang, C.; Cui, H.; Sun, G.; Qi, X.; Yao, X. Mitochondrial dysfunction in age-related sarcopenia: Mechanistic insights, diagnostic advances, and therapeutic prospects. Front. Cell Dev. Biol. 2025, 13, 1590524. [Google Scholar] [CrossRef] [Scilit]
  87. Jeong, I.; Cho, E.J.; Yook, J.S.; Choi, Y.; Park, D.H.; Kang, J.H.; Lee, S.H.; Seo, D.Y.; Jung, S.J.; Kwak, H.B. Mitochondrial Adaptations in Aging Skeletal Muscle: Implications for Resistance Exercise Training to Treat Sarcopenia. Life 2024, 14, 962. [Google Scholar] [CrossRef] [Scilit]
  88. Yuan, X.; Ouedraogo, S.Y.; Jammeh, M.L.; Simbiliyabo, L.; Jabang, J.N.; Jaw, M.; Darboe, A.; Tan, Y.; Bajinka, O. Can microbiota gut-brain axis reverse neurodegenerative disorders in human? Ageing Res. Rev. 2025, 104, 102664. [Google Scholar] [CrossRef] [Scilit]
  89. Eggelbusch, M.; Shi, A.; Broeksma, B.C.; Vázquez-Cruz, M.; Soares, M.N.; de Wit, G.M.J.; Everts, B.; Jaspers, R.T.; Wüst, R.C.I. The NLRP3 inflammasome contributes to inflammation-induced morphological and metabolic alterations in skeletal muscle. J. Cachexia Sarcopenia Muscle 2022, 13, 3048–3061. [Google Scholar] [CrossRef] [Scilit]
  90. Jimenez-Gutierrez, G.E.; Martínez-Gómez, L.E.; Martínez-Armenta, C.; Pineda, C.; Martínez-Nava, G.A.; Lopez-Reyes, A. Molecular Mechanisms of Inflammation in Sarcopenia: Diagnosis and Therapeutic Update. Cells 2022, 11, 2359. [Google Scholar] [CrossRef] [Scilit]
  91. Jorquera, G.; Russell, J.; Monsalves-Álvarez, M.; Cruz, G.; Valladares-Ide, D.; Basualto-Alarcón, C.; Barrientos, G.; Estrada, M.; Llanos, P. NLRP3 Inflammasome: Potential Role in Obesity Related Low-Grade Inflammation and Insulin Resistance in Skeletal Muscle. Int. J. Mol. Sci. 2021, 22, 3254. [Google Scholar] [CrossRef] [Scilit]
  92. Romanello, V. The Interplay between Mitochondrial Morphology and Myomitokines in Aging Sarcopenia. Int. J. Mol. Sci. 2020, 22, 91. [Google Scholar] [CrossRef] [Scilit]
  93. Gouspillou, G.; Bourdel-Marchasson, I.; Rouland, R.; Calmettes, G.; Franconi, J.M.; Deschodt-Arsac, V.; Diolez, P. Alteration of mitochondrial oxidative phosphorylation in aged skeletal muscle involves modification of adenine nucleotide translocator. Biochim. Biophys. Acta 2010, 1797, 143–151. [Google Scholar] [CrossRef] [Scilit]
  94. McKee, A.; Morley, J.E.; Matsumoto, A.M.; Vinik, A. Sarcopenia: An Endocrine Disorder? Endocr. Pract. 2017, 23, 1140–1149. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  95. Tezze, C.; Sandri, M.; Tessari, P. Anabolic Resistance in the Pathogenesis of Sarcopenia in the Elderly: Role of Nutrition and Exercise in Young and Old People. Nutrients 2023, 15, 4073. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  96. Ferrari, U.; Schmidmaier, R.; Jung, T.; Reincke, M.; Martini, S.; Schoser, B.; Bidlingmaier, M.; Drey, M. IGF-I/IGFBP3/ALS Deficiency in Sarcopenia: Low GHBP Suggests GH Resistance in a Subgroup of Geriatric Patients. J. Clin. Endocrinol. Metab. 2021, 106, e1698–e1707. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  97. Deschenes, M.R.; Flannery, R.; Hawbaker, A.; Patek, L.; Mifsud, M. Adaptive Remodeling of the Neuromuscular Junction with Aging. Cells 2022, 11, 1150. [Google Scholar] [CrossRef] [Scilit]
  98. Chugh, D.; Iyer, C.C.; Wang, X.; Bobbili, P.; Rich, M.M.; Arnold, W.D. Neuromuscular junction transmission failure is a late phenotype in aging mice. Neurobiol. Aging 2020, 86, 182–190. [Google Scholar] [CrossRef] [Scilit]
  99. Arnold, W.D.; Clark, B.C. Neuromuscular junction transmission failure in aging and sarcopenia: The nexus of the neurological and muscular systems. Ageing Res. Rev. 2023, 89, 101966. [Google Scholar] [CrossRef] [Scilit]
  100. Hosoi, T.; Yakabe, M.; Hashimoto, S.; Akishita, M.; Ogawa, S. The roles of sex hormones in the pathophysiology of age-related sarcopenia and frailty. Reprod. Med. Biol. 2024, 23, e12569. [Google Scholar] [CrossRef] [Scilit]
  101. Morley, J.E.; Malmstrom, T.K. Frailty, sarcopenia, and hormones. Endocrinol. Metab. Clin. N. Am. 2013, 42, 391–405. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  102. Conzade, R.; Grill, E.; Bischoff-Ferrari, H.A.; Ferrari, U.; Horsch, A.; Koenig, W.; Peters, A.; Thorand, B. Vitamin D in Relation to Incident Sarcopenia and Changes in Muscle Parameters Among Older Adults: The KORA-Age Study. Calcif. Tissue Int. 2019, 105, 173–182. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  103. Merchant, R.A.; Chan, Y.H.; Anbarasan, D.; Aprahamian, I. Association of Motoric Cognitive Risk Syndrome with Sarcopenia and Systemic Inflammation in Pre-Frail Older Adults. Brain Sci. 2023, 13, 936. [Google Scholar] [CrossRef] [Scilit]
  104. Liguori, I.; Russo, G.; Curcio, F.; Bulli, G.; Aran, L.; Della-Morte, D.; Gargiulo, G.; Testa, G.; Cacciatore, F.; Bonaduce, D.; et al. Oxidative stress, aging, and diseases. Clin. Interv. Aging 2018, 13, 757–772. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  105. Powers, S.K.; Ji, L.L.; Kavazis, A.N.; Jackson, M.J. Reactive oxygen species: Impact on skeletal muscle. Compr. Physiol. 2011, 1, 941–969. [Google Scholar] [CrossRef] [Scilit]
  106. Frijhoff, J.; Winyard, P.G.; Zarkovic, N.; Davies, S.S.; Stocker, R.; Cheng, D.; Knight, A.R.; Taylor, E.L.; Oettrich, J.; Ruskovska, T.; et al. Clinical Relevance of Biomarkers of Oxidative Stress. Antioxid. Redox Signal. 2015, 23, 1144–1170. [Google Scholar] [CrossRef] [Scilit]
  107. Chandrasekaran, K.; Giordano, T.; Brady, D.R.; Stoll, J.; Martin, L.J.; Rapoport, S.I. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. Brain Res. Mol. Brain Res. 1994, 24, 336–340. [Google Scholar] [CrossRef] [Scilit]
  108. Picca, A.; Lozanoska-Ochser, B.; Calvani, R.; Coelho-Júnior, H.J.; Leewenburgh, C.; Marzetti, E. Inflammatory, mitochondrial, and senescence-related markers: Underlying biological pathways of muscle aging and new therapeutic targets. Exp. Gerontol. 2023, 178, 112204. [Google Scholar] [CrossRef] [Scilit]
  109. Scisciola, L.; Fontanella, R.A.; Surina; Cataldo, V.; Paolisso, G.; Barbieri, M. Sarcopenia and Cognitive Function: Role of Myokines in Muscle Brain Cross-Talk. Life 2021, 11, 173. [Google Scholar] [CrossRef] [Scilit]
  110. Ascenzi, F.; Barberi, L.; Dobrowolny, G.; Villa Nova Bacurau, A.; Nicoletti, C.; Rizzuto, E.; Rosenthal, N.; Scicchitano, B.M.; Musarò, A. Effects of IGF-1 isoforms on muscle growth and sarcopenia. Aging Cell 2019, 18, e12954. [Google Scholar] [CrossRef] [Scilit]
  111. Bian, A.; Ma, Y.; Zhou, X.; Guo, Y.; Wang, W.; Zhang, Y.; Wang, X. Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly. BMC Musculoskelet. Disord. 2020, 21, 214. [Google Scholar] [CrossRef] [Scilit]
  112. Hosoyama, T.; Iida, H.; Kawai-Takaishi, M.; Watanabe, K. Vitamin D Inhibits Myogenic Cell Fusion and Expression of Fusogenic Genes. Nutrients 2020, 12, 2192. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  113. Liu, D.; Wang, S.; Liu, S.; Wang, Q.; Che, X.; Wu, G. Frontiers in sarcopenia: Advancements in diagnostics, molecular mechanisms, and therapeutic strategies. Mol. Aspects Med. 2024, 97, 101270. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  114. Yang, W.; Si, S.C.; Wang, W.H.; Li, J.; Ma, Y.X.; Zhao, H.; Liu, J. Gut dysbiosis in primary sarcopenia: Potential mechanisms and implications for novel microbiome-based therapeutic strategies. Front. Microbiol. 2025, 16, 1526764. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  115. Salom Vendrell, C.; García Tercero, E.; Moro Hernández, J.B.; Cedeno-Veloz, B.A. Sarcopenia as a Little-Recognized Comorbidity of Type II Diabetes Mellitus: A Review of the Diagnosis and Treatment. Nutrients 2023, 15, 4149. [Google Scholar] [CrossRef] [Scilit]
  116. Bahadoran, Z.; Mirmiran, P.; Ghasemi, A. Type 2 diabetes-related sarcopenia: Role of nitric oxide. Nutr. Metab. 2024, 21, 107. [Google Scholar] [CrossRef] [Scilit]
  117. Lin, C.C.; Ou, H.Y.; Hsu, H.Y.; Cheng, K.P.; Hsieh, T.J.; Yeh, C.H.; Su, F.C.; Kuo, L.C. Beyond Sarcopenia: Older adults with type II diabetes mellitus tend to experience an elevated risk of poor dynamic balance-a case-control study. BMC Geriatr. 2022, 22, 138. [Google Scholar] [CrossRef] [Scilit]
  118. Liu, Z.; Guo, Y.; Zheng, C. Type 2 diabetes mellitus related sarcopenia: A type of muscle loss distinct from sarcopenia and disuse muscle atrophy. Front. Endocrinol. 2024, 15, 1375610. [Google Scholar] [CrossRef] [Scilit]
  119. Lee, C.G.; Boyko, E.J.; Strotmeyer, E.S.; Lewis, C.E.; Cawthon, P.M.; Hoffman, A.R.; Everson-Rose, S.A.; Barrett-Connor, E.; Orwoll, E.S. Osteoporotic Fractures in Men Study Research Group. Association between insulin resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. J. Am. Geriatr. Soc. 2011, 59, 1217–1224. [Google Scholar] [CrossRef] [Scilit]
  120. Sanz-Cánovas, J.; López-Sampalo, A.; Cobos-Palacios, L.; Ricci, M.; Hernández-Negrín, H.; Mancebo-Sevilla, J.J.; Álvarez-Recio, E.; López-Carmona, M.D.; Pérez-Belmonte, L.M.; Gómez-Huelgas, R.; et al. Management of Type 2 Diabetes Mellitus in Elderly Patients with Frailty and/or Sarcopenia. Int. J. Environ. Res. Public Health 2022, 19, 8677. [Google Scholar] [CrossRef] [Scilit]
  121. Landi, F.; Onder, G.; Bernabei, R. Sarcopenia and diabetes: Two sides of the same coin. J. Am. Med. Dir. Assoc. 2013, 14, 540–541. [Google Scholar] [CrossRef] [Scilit]
  122. Pereira, S.; Marliss, E.B.; Morais, J.A.; Chevalier, S.; Gougeon, R. Insulin resistance of protein metabolism in type 2 diabetes. Diabetes 2008, 57, 56–63. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  123. Nygren, J.; Nair, K.S. Differential regulation of protein dynamics in splanchnic and skeletal muscle beds by insulin and amino acids in healthy human subjects. Diabetes 2003, 52, 1377–1385. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  124. Tan, S.; Gunendi, Z.; Meray, J.; Yetkin, İ. The evaluation of muscle strength and architecture in type 1 diabetes mellitus: A cross-sectional study. BMC Endocr. Disord. 2022, 22, 153. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  125. Tabara, Y.; Ikezoe, T.; Yamanaka, M.; Setoh, K.; Segawa, H.; Kawaguchi, T.; Kosugi, S.; Nakayama, T.; Ichihashi, N.; Tsuboyama, T.; et al. Advanced Glycation End Product Accumulation Is Associated with Low Skeletal Muscle Mass, Weak Muscle Strength, and Reduced Bone Density: The Nagahama Study. J. Gerontol. A Biol. Sci. Med. Sci. 2019, 74, 1446–1453. [Google Scholar] [CrossRef] [Scilit]
  126. Mesinovic, J.; Zengin, A.; De Courten, B.; Ebeling, P.R.; Scott, D. Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship. Diabetes Metab. Syndr. Obes. 2019, 12, 1057–1072. [Google Scholar] [CrossRef] [Scilit]
  127. Giannakogeorgou, A.; Roden, M.; Pafili, K. Diabetes mellitus as a multisystem disease: Understanding subtypes, complications, and the link with steatotic liver diseases in humans. Hormones 2025. [Google Scholar] [CrossRef] [Scilit]
  128. Park, Y.; Kim, S.T.; Kim, Y.M.; Han, H.S.; Yoon, Y.S. Role of diabetes-related inflammation in pancreatic cancer evaluated by aptamer-based detection of circulating tumor cells in a streptozotocin-induced Panc02-transplanted murine model. Ann. Hepatobiliary Pancreat. Surg. 2025, 29, 343–352. [Google Scholar] [CrossRef] [Scilit]
  129. Haddad, F.; Zaldivar, F.; Cooper, D.M.; Adams, G.R. IL-6-induced skeletal muscle atrophy. J. Appl. Physiol. 2005, 98, 911–917. [Google Scholar] [CrossRef] [Scilit]
  130. Goyal, R.; Faizy, A.F.; Siddiqui, S.S.; Singhai, M. Evaluation of TNF-α and IL-6 Levels in Obese and Non-obese Diabetics: Pre- and Postinsulin Effects. N. Am. J. Med. Sci. 2012, 4, 180–184. [Google Scholar] [CrossRef] [Scilit]
  131. Liu, Y.; Li, Z.; Wang, R.; Zhang, J.; Gerstein, H.; Zhao, A.; Zhang, C.; Lip, G.Y.H.; Van Spall, H.G.C.; Li, G. Relationship between sarcopenia and type 2 diabetes mellitus among adults with prediabetes: Evidence from a prospective cohort study. Diabetol. Metab. Syndr. 2025, 17, 379. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  132. Chen, H.; Huang, X.; Dong, M.; Wen, S.; Zhou, L.; Yuan, X. The Association Between Sarcopenia and Diabetes: From Pathophysiology Mechanism to Therapeutic Strategy. Diabetes Metab. Syndr. Obes. 2023, 16, 1541–1554. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  133. Xu, Y.; Hu, T.; Shen, Y.; Wang, Y.; Bao, Y.; Ma, X. Association of skeletal muscle mass and its change with diabetes occurrence: A population-based cohort study. Diabetol. Metab. Syndr. 2023, 15, 53. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  134. Ye, C.; Kong, L.; Wang, Y.; Zheng, J.; Xu, M.; Xu, Y.; Li, M.; Zhao, Z.; Lu, J.; Chen, Y.; et al. Causal associations of sarcopenia-related traits with cardiometabolic disease and Alzheimer’s disease and the mediating role of insulin resistance: A Mendelian randomization study. Aging Cell 2023, 22, e13923. [Google Scholar] [CrossRef] [Scilit]
  135. Ni, Y.; Fan, D. Diabetes mellitus is a risk factor for low bone mass-related fractures: A meta-analysis of cohort studies. Medicine 2017, 96, e8811. [Google Scholar] [CrossRef] [Scilit]
  136. Pechmann, L.M.; Petterle, R.R.; Moreira, C.A.; Borba, V.Z.C. Osteosarcopenia and trabecular bone score in patients with type 2 diabetes mellitus. Arch. Endocrinol. Metab. 2021, 65, 801–810. [Google Scholar] [CrossRef] [Scilit]
  137. Sipilä, S.; Törmäkangas, T.; Sillanpää, E.; Aukee, P.; Kujala, U.M.; Kovanen, V.; Laakkonen, E.K. Muscle and bone mass in middle-aged women: Role of menopausal status and physical activity. J. Cachexia Sarcopenia Muscle 2020, 11, 698–709. [Google Scholar] [CrossRef] [Scilit]
  138. Abbatecola, A.M.; Paolisso, G.; Fattoretti, P.; Evans, W.J.; Fiore, V.; Dicioccio, L.; Lattanzio, F. Discovering pathways of sarcopenia in older adults: A role for insulin resistance on mitochondria dysfunction. J. Nutr. Health Aging 2011, 15, 890–895. [Google Scholar] [CrossRef] [Scilit]
  139. Greco, E.A.; Pietschmann, P.; Migliaccio, S. Osteoporosis and Sarcopenia Increase Frailty Syndrome in the Elderly. Front. Endocrinol. 2019, 10, 255. [Google Scholar] [CrossRef] [Scilit]
  140. Çakmak, G.; Ganidağlı, S.; Efendioğlu, E.M.; Öztürk, E.; Öztürk, Z.A. Do Long-Term Complications of Type 2 Diabetes Increase Susceptibility to Geriatric Syndromes in Older Adults? Medicina 2021, 57, 968. [Google Scholar] [CrossRef] [Scilit]
  141. Hashimoto, Y.; Takahashi, F.; Okamura, T.; Hamaguchi, M.; Fukui, M. Diet, exercise, and pharmacotherapy for sarcopenia in people with diabetes. Metabolism 2023, 144, 155585. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  142. Denison, H.J.; Cooper, C.; Sayer, A.A.; Robinson, S.M. Prevention and optimal management of sarcopenia: A review of combined exercise and nutrition interventions to improve muscle outcomes in older people. Clin. Interv. Aging 2015, 10, 859–869. [Google Scholar] [CrossRef] [Scilit]
  143. Gómez-Cabello, A.; Vicente Rodríguez, G.; Vila-Maldonado, S.; Casajús, J.A.; Ara, I. Aging and body composition: The sarcopenic obesity in Spain. Nutr. Hosp. 2012, 27, 22–30. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  144. Wei, S.; Nguyen, T.T.; Zhang, Y.; Ryu, D.; Gariani, K. Sarcopenic obesity: Epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Front. Endocrinol. 2023, 14, 1185221. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  145. Donini, L.M.; Busetto, L.; Bischoff, S.C.; Cederholm, T.; Ballesteros-Pomar, M.D.; Batsis, J.A.; Bauer, J.M.; Boirie, Y.; Cruz-Jentoft, A.J.; Dicker, D.; et al. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obes. Facts 2022, 15, 321–335. [Google Scholar] [CrossRef] [Scilit]
  146. Batsis, J.A.; Villareal, D.T. Sarcopenic obesity in older adults: Aetiology, epidemiology and treatment strategies. Nat. Rev. Endocrinol. 2018, 14, 513–537. [Google Scholar] [CrossRef] [Scilit]
  147. Nedelcu, A.D.; Uzun, A.B.; Ciortea, V.M.; Irsay, L.; Stanciu, L.E.; Iliescu, D.M.; Popa, F.L.; Iliescu, M.G. Genetic Patterns Related with the Development and Progression of Sarcopenia and Sarcopenic Obesity: A Systematic Review. Medicina 2025, 61, 866. [Google Scholar] [CrossRef] [Scilit]
  148. Prado, C.M.; Batsis, J.A.; Donini, L.M.; Gonzalez, M.C.; Siervo, M. Sarcopenic obesity in older adults: A clinical overview. Nat. Rev. Endocrinol. 2024, 20, 261–277. [Google Scholar] [CrossRef] [Scilit]
  149. Oliveira, T.M.; Roriz, A.K.C.; Barreto-Medeiros, J.M.; Ferreira, A.J.F.; Ramos, L. Sarcopenic obesity in community-dwelling older women, determined by different diagnostic methods. Nutr. Hosp. 2019, 36, 1267–1272. [Google Scholar] [CrossRef] [Scilit]
  150. Abete, I.; Konieczna, J.; Zulet, M.A.; Galmés-Panades, A.M.; Ibero-Baraibar, I.; Babio, N.; Estruch, R.; Vidal, J.; Toledo, E.; Razquin, C.; et al. Association of lifestyle factors and inflammation with sarcopenic obesity: Data from the PREDIMED-Plus trial. J. Cachexia Sarcopenia Muscle 2019, 10, 974–984. [Google Scholar] [CrossRef] [Scilit]
  151. Minniti, G.; Pescinini-Salzedas, L.M.; Minniti, G.; Laurindo, L.F.; Barbalho, S.M.; Vargas Sinatora, R.; Sloan, L.A.; Haber, R.S.A.; Araújo, A.C.; Quesada, K.; et al. Organokines, Sarcopenia, and Metabolic Repercussions: The Vicious Cycle and the Interplay with Exercise. Int. J. Mol. Sci. 2022, 23, 13452. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  152. Aslam, M.A.; Ma, E.B.; Huh, J.Y. Pathophysiology of sarcopenia: Genetic factors and their interplay with environmental factors. Metabolism 2023, 149, 155711. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  153. Semenova, E.A.; Pranckevičienė, E.; Bondareva, E.A.; Gabdrakhmanova, L.J.; Ahmetov, I.I. Identification and Characterization of Genomic Predictors of Sarcopenia and Sarcopenic Obesity Using UK Biobank Data. Nutrients 2023, 15, 758. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  154. Feng, Z.; Xia, J.; Yu, J.; Wang, J.; Yin, S.; Yang, J.; Wu, T.; Zhang, Z.; Yan, W.; Wang, S.; et al. Pathophysiological Mechanisms Underlying Sarcopenia and Sarcopenic Obesity: A Systematic Review and Meta-Analysis of Biomarker Evidence. Int. J. Mol. Sci. 2025, 26, 5113. [Google Scholar] [CrossRef] [Scilit]
  155. Silva, J.K.; Aguiar, O.B.; Diniz, M.F.H.S.; Braga, J.U.; Griep, R.H.; Fonseca, M.J.M.D. Performance of the “a body shape index” as a discriminator of obesity and sarcopenic obesity—ELSA-Brasil. Cien. Saude Colet. 2025, 30, e03162023. [Google Scholar] [CrossRef] [Scilit]
  156. Pavlovskaya, E.V.; Kislyak, O.A.; Starodubova, A.V. Principles of diet therapy for sarcopenic obesity: A review. Ter. Arkhiv 2025, 97, 571–579. [Google Scholar] [CrossRef] [Scilit]
  157. Briguglio, M.; Sirtori, P.; Mangiavini, L.; Wainwright, T.W.; Peretti, G.M.; Banfi, G. NCPD Tests: Undernutrition, Sarcopenia, Sarcopenic Obesity, and Sarcopenic Undernutrition: A Cross-sectional View on Patients Before Total Joint Arthroplasty. Orthop. Nurs. 2024, 43, E19. [Google Scholar] [CrossRef] [Scilit]
  158. Calvani, R.; Marini, F.; Cesari, M.; Buford, T.W.; Manini, T.M.; Pahor, M.; Leeuwenburgh, C.; Bernabei, R.; Landi, F.; Marzetti, E. Systemic inflammation, body composition, and physical performance in old community-dwellers. J. Cachexia Sarcopenia Muscle 2017, 8, 69–77. [Google Scholar] [CrossRef] [Scilit]
  159. Batsis, J.A.; Mackenzie, T.A.; Barre, L.K.; Lopez-Jimenez, F.; Bartels, S.J. Sarcopenia, sarcopenic obesity and mortality in older adults: Results from the National Health and Nutrition Examination Survey III. Eur. J. Clin. Nutr. 2014, 68, 1001–1007. [Google Scholar] [CrossRef] [Scilit]
  160. Tyrovolas, S.; Koyanagi, A.; Olaya, B.; Ayuso-Mateos, J.L.; Miret, M.; Chatterji, S.; Tobiasz-Adamczyk, B.; Koskinen, S.; Leonardi, M.; Haro, J.M. Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: A multi-continent study. J. Cachexia Sarcopenia Muscle 2016, 7, 312–321. [Google Scholar] [CrossRef] [Scilit]
  161. Sugimoto, T.; Kuroda, Y.; Matsumoto, N.; Uchida, K.; Kishino, Y.; Saji, N.; Niida, S.; Sakurai, T. Cross-Sectional Associations of Sarcopenia and Its Components with Neuropsychological Performance among Memory Clinic Patients with Mild Cognitive Impairment and Alzheimer’s Disease. J. Frailty Aging 2022, 11, 182–189. [Google Scholar] [CrossRef] [Scilit]
  162. Su, C.; Zhang, S.; Zheng, Q.; Miao, J.; Guo, J. Prevalence and correlation of sarcopenia with Alzheimer’s disease: A systematic review and meta-analysis. PLoS ONE 2025, 20, e0318920. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  163. Hart, A.; Cordova-Rivera, L.; Barker, F.; Sayer, A.A.; Granic, A.; Yarnall, A.J. The prevalence of sarcopenia in Parkinson’s disease and related disorders- a systematic review. Neurol. Sci. 2023, 44, 4205–4217. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  164. Beeri, M.S.; Leugrans, S.E.; Delbono, O.; Bennett, D.A.; Buchman, A.S. Sarcopenia is associated with incident Alzheimer’s dementia, mild cognitive impairment, and cognitive decline. J. Am. Geriatr. Soc. 2021, 69, 1826–1835. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  165. Fujisawa, C.; Umegaki, H.; Okamoto, K.; Nakashima, H.; Kuzuya, M.; Toba, K.; Sakurai, T. Physical Function Differences Between the Stages from Normal Cognition to Moderate Alzheimer Disease. J. Am. Med. Dir. Assoc. 2017, 18, 368.e9–368.e15. [Google Scholar] [CrossRef] [Scilit]
  166. Murata, S.; Ono, R.; Sugimoto, T.; Toba, K.; Sakurai, T. Functional Decline and Body Composition Change in Older Adults with Alzheimer Disease: A Retrospective Cohort Study at a Japanese Memory Clinic. Alzheimer Dis. Assoc. Disord. 2021, 35, 36–43. [Google Scholar] [CrossRef] [Scilit]
  167. Michaud, M.; Balardy, L.; Moulis, G.; Gaudin, C.; Peyrot, C.; Vellas, B.; Cesari, M.; Nourhashemi, F. Proinflammatory cytokines, aging, and age-related diseases. J. Am. Med. Dir. Assoc. 2013, 14, 877–882. [Google Scholar] [CrossRef] [Scilit]
  168. Mecocci, P.; Boccardi, V.; Cecchetti, R.; Bastiani, P.; Scamosci, M.; Ruggiero, C.; Baroni, M. A Long Journey into Aging, Brain Aging, and Alzheimer’s Disease Following the Oxidative Stress Tracks. J. Alzheimers Dis. 2018, 62, 1319–1335. [Google Scholar] [CrossRef] [Scilit]
  169. Cai, Y.; Feng, F.; Wei, Q.; Jiang, Z.; Ou, R.; Shang, H. Sarcopenia in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis. Front. Neurol. 2021, 12, 598035. [Google Scholar] [CrossRef] [Scilit]
  170. Lima, D.P.; de Almeida, S.B.; Bonfadini, J.C.; de Luna, J.R.G.; de Alencar, M.S.; Pinheiro-Neto, E.B.; Viana-Júnior, A.B.; Veras, S.R.O.; Sobreira-Neto, M.A.; Roriz-Filho, J.S.; et al. Clinical correlates of sarcopenia and falls in Parkinson’s disease. PLoS ONE 2020, 15, e0227238. [Google Scholar] [CrossRef] [Scilit]
  171. Drey, M.; Krieger, B.; Sieber, C.C.; Bauer, J.M.; Hettwer, S.; Bertsch, T.; DISARCO Study Group. Motoneuron loss is associated with sarcopenia. J. Am. Med. Dir. Assoc. 2014, 15, 435–439. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  172. Krenovsky, J.P.; Bötzel, K.; Ceballos-Baumann, A.; Fietzek, U.M.; Schoser, B.; Maetzler, W.; Ferrari, U.; Drey, M. Interrelation between Sarcopenia and the Number of Motor Neurons in Patients with Parkinsonian Syndromes. Gerontology 2020, 66, 409–415. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  173. Basualto-Alarcón, C.; Varela, D.; Duran, J.; Maass, R.; Estrada, M. Sarcopenia and Androgens: A Link between Pathology and Treatment. Front. Endocrinol. 2014, 5, 217. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  174. Amini, N.; Ibn Hach, M.; Lapauw, L.; Dupont, J.; Vercauteren, L.; Verschueren, S.; Tournoy, J.; Gielen, E. Meta-analysis on the interrelationship between sarcopenia and mild cognitive impairment, Alzheimer’s disease and other forms of dementia. J. Cachexia Sarcopenia Muscle 2024, 15, 1240–1253. [Google Scholar] [CrossRef] [Scilit]
  175. Kondoh, H.; Kameda, M. Metabolites in aging and aging-relevant diseases: Frailty, sarcopenia and cognitive decline. Geriatr. Gerontol. Int. 2024, 24 (Suppl. S1), 44–48. [Google Scholar] [CrossRef] [Scilit]
  176. Chen, X.; Cao, M.; Liu, M.; Liu, S.; Zhao, Z.; Chen, H. Association between sarcopenia and cognitive impairment in the older people: A meta-analysis. Eur. Geriatr. Med. 2022, 13, 771–787. [Google Scholar] [CrossRef] [Scilit]
  177. Cesari, M.; Landi, F.; Vellas, B.; Bernabei, R.; Marzetti, E. Sarcopenia and physical frailty: Two sides of the same coin. Front. Aging Neurosci. 2014, 6, 192. [Google Scholar] [CrossRef] [Scilit]
  178. Kosyreva, A.M.; Sentyabreva, A.V.; Tsvetkov, I.S.; Makarova, O.V. Alzheimer’s Disease and Inflammaging. Brain Sci. 2022, 12, 1237. [Google Scholar] [CrossRef] [Scilit]
  179. Du, H.; Yu, M.; Xue, H.; Lu, X.; Chang, Y.; Li, Z. Association between sarcopenia and cognitive function in older Chinese adults: Evidence from the China health and retirement longitudinal study. Front. Public Health 2022, 10, 1078304. [Google Scholar] [CrossRef] [Scilit]
  180. Boyle, P.A.; Buchman, A.S.; Wilson, R.S.; Leurgans, S.E.; Bennett, D.A. Association of muscle strength with the risk of Alzheimer disease and the rate of cognitive decline in community-dwelling older persons. Arch. Neurol. 2009, 66, 1339–1344. [Google Scholar] [CrossRef] [Scilit]
  181. Casati, M.; Costa, A.S.; Capitanio, D.; Ponzoni, L.; Ferri, E.; Agostini, S.; Lori, E. The Biological Foundations of Sarcopenia: Established and Promising Markers. Front. Med. 2019, 6, 184. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  182. Shigemoto, K.; Kubo, S.; Mori, S.; Yamada, S.; Akiyoshi, T.; Miyazaki, T. Muscle weakness and neuromuscular junctions in aging and disease. Geriatr. Gerontol. Int. 2010, 10 (Suppl. S1), S137–S147. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  183. Moreira-Pais, A.; Ferreira, R.; Oliveira, P.A.; Duarte, J.A. A neuromuscular perspective of sarcopenia pathogenesis: Deciphering the signaling pathways involved. Geroscience 2022, 44, 1199–1213. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  184. Rudolf, R.; Khan, M.M.; Labeit, S.; Deschenes, M.R. Degeneration of neuromuscular junction in age and dystrophy. Front. Aging Neurosci. 2014, 6, 99. [Google Scholar] [CrossRef] [Scilit]
  185. Yang, Y.; Xiao, M.; Leng, L.; Jiang, S.; Feng, L.; Pan, G.; Li, Z.; Wang, Y.; Wang, J.; Wen, Y.; et al. A systematic review and meta-analysis of the prevalence and correlation of mild cognitive impairment in sarcopenia. J. Cachexia Sarcopenia Muscle 2023, 14, 45–56. [Google Scholar] [CrossRef] [Scilit]
  186. Zhang, J.; Jia, X.; Li, Y.; Li, H.; Yang, Q. The longitudinal bidirectional association between sarcopenia and cognitive function in community-dwelling older adults: Findings from the China Health and Retirement Longitudinal Study. J. Glob. Health 2023, 13, 04182. [Google Scholar] [CrossRef] [Scilit]
  187. Cacciatore, S.; Calvani, R.; Marzetti, E.; Picca, A.; Coelho-Júnior, H.J.; Martone, A.M.; Massaro, C.; Tosato, M.; Landi, F. Low Adherence to Mediterranean Diet Is Associated with Probable Sarcopenia in Community-Dwelling Older Adults: Results from the Longevity Check-Up (Lookup) 7+ Project. Nutrients 2023, 15, 1026. [Google Scholar] [CrossRef] [Scilit]
  188. Peng, T.C.; Chen, W.L.; Wu, L.W.; Chang, Y.W.; Kao, T.W. Sarcopenia and cognitive impairment: A systematic review and meta-analysis. Clin Nutr. 2020, 39, 2695–2701. [Google Scholar] [CrossRef] [Scilit]
  189. Yuan, S.; Larsson, S.C. Epidemiology of sarcopenia: Prevalence, risk factors, and consequences. Metabolism 2023, 144, 155533. [Google Scholar] [CrossRef] [Scilit]
  190. Mitchell, W.K.; Williams, J.; Atherton, P.; Larvin, M.; Lund, J.; Narici, M. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front. Physiol. 2012, 3, 260. [Google Scholar] [CrossRef] [Scilit]
  191. Seo, M.W.; Jung, S.W.; Kim, S.W.; Lee, J.M.; Jung, H.C.; Song, J.K. Effects of 16 Weeks of Resistance Training on Muscle Quality and Muscle Growth Factors in Older Adult Women with Sarcopenia: A Randomized Controlled Trial. Int. J. Environ. Res. Public Health 2021, 18, 6762. [Google Scholar] [CrossRef] [Scilit]
  192. Billot, M.; Calvani, R.; Urtamo, A.; Sánchez-Sánchez, J.L.; Ciccolari-Micaldi, C.; Chang, M.; Roller-Wirnsberger, R.; Wirnsberger, G.; Sinclair, A.; Vaquero-Pinto, N.; et al. Preserving Mobility in Older Adults with Physical Frailty and Sarcopenia: Opportunities, Challenges, and Recommendations for Physical Activity Interventions. Clin. Interv. Aging 2020, 15, 1675–1690. [Google Scholar] [CrossRef] [Scilit]
  193. Marzetti, E.; Calvani, R.; Tosato, M.; Cesari, M.; Di Bari, M.; Cherubini, A.; Collamati, A.; D’Angelo, E.; Pahor, M.; Bernabei, R.; et al. Sarcopenia: An overview. Aging Clin. Exp. Res. 2017, 29, 11–17. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  194. Sun, R.; Wan, J.; Tang, J.; Deng, Y.; Zhang, M.; Liu, C.; Li, J.; Zhang, Q. Effectiveness of resistance training on body composition, muscle strength, and biomarker in sarcopenic older adults: A meta-analysis of randomized controlled trials. Arch. Gerontol. Geriatr. 2025, 128, 105595. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  195. Welle, S. Cellular and molecular basis of age-related sarcopenia. Can. J. Appl. Physiol. 2002, 27, 19–41. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  196. Aragon, A.A.; Tipton, K.D.; Schoenfeld, B.J. Age-related muscle anabolic resistance: Inevitable or preventable? Nutr. Rev. 2023, 81, 441–454. [Google Scholar] [CrossRef] [Scilit]
  197. Ferrucci, L.; Fabbri, E. Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty. Nat. Rev. Cardiol. 2018, 15, 505–522. [Google Scholar] [CrossRef] [Scilit]
  198. Dalle, S.; Rossmeislova, L.; Koppo, K. The Role of Inflammation in Age-Related Sarcopenia. Front. Physiol. 2017, 8, 1045. [Google Scholar] [CrossRef] [Scilit]
  199. Liu, G.; Jiang, S.; Xie, W.; Liu, X.; Yang, G.; Lu, W.; Li, H.; Liu, Z.; Xiao, W.; Li, Y. Biomarkers for sarcopenia, muscle mass, muscle strength, and physical performance: An umbrella review. J. Transl. Med. 2025, 23, 650. [Google Scholar] [CrossRef] [Scilit]
  200. Lu, Y.; Niti, M.; Yap, K.B.; Tan, C.T.Y.; Zin Nyunt, M.S.; Feng, L.; Tan, B.Y.; Chan, G.; Khoo, S.A.; Chan, S.M.; et al. Assessment of Sarcopenia Among Community-Dwelling At-Risk Frail Adults Aged 65 Years and Older Who Received Multidomain Lifestyle Interventions: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw. Open 2019, 2, e1913346. [Google Scholar] [CrossRef] [Scilit]
  201. Paterson, D.H.; Warburton, D.E. Physical activity and functional limitations in older adults: A systematic review related to Canada’s Physical Activity Guidelines. Int. J. Behav. Nutr. Phys. Act. 2010, 7, 38. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  202. Beckwée, D.; Delaere, A.; Aelbrecht, S.; Baert, V.; Beaudart, C.; Bruyere, O.; de Saint-Hubert, M.; Bautmans, I. Exercise Interventions for the Prevention and Treatment of Sarcopenia. A Systematic Umbrella Review. J. Nutr. Health Aging 2019, 23, 494–502. [Google Scholar] [CrossRef] [Scilit]
  203. Chang, K.V.; Wu, W.T.; Chen, Y.H.; Chen, L.R.; Hsu, W.H.; Lin, Y.L.; Han, D.S. Enhanced serum levels of tumor necrosis factor-α, interleukin-1β, and -6 in sarcopenia: Alleviation through exercise and nutrition intervention. Aging 2023, 15, 13471–13485. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  204. Grenham, S.; Clarke, G.; Cryan, J.F.; Dinan, T.G. Brain-gut-microbe communication in health and disease. Front. Physiol. 2011, 2, 94. [Google Scholar] [CrossRef] [Scilit]
  205. Carabotti, M.; Scirocco, A.; Maselli, M.A.; Severi, C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Ann. Gastroenterol. 2015, 28, 203–209. [Google Scholar] [PubMed]
  206. Kim, C.S.; Cha, L.; Sim, M.; Jung, S.; Chun, W.Y.; Baik, H.W.; Shin, D.M. Probiotic Supplementation Improves Cognitive Function and Mood with Changes in Gut Microbiota in Community-Dwelling Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. J. Gerontol. A Biol. Sci. Med. Sci. 2021, 76, 32–40. [Google Scholar] [CrossRef] [Scilit]
  207. Kesika, P.; Suganthy, N.; Sivamaruthi, B.S.; Chaiyasut, C. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer’s disease. Life Sci. 2021, 264, 118627. [Google Scholar] [CrossRef] [Scilit]
  208. Yang, J.; Liang, J.; Hu, N.; He, N.; Liu, B.; Liu, G.; Qin, Y. The Gut Microbiota Modulates Neuroinflammation in Alzheimer’s Disease: Elucidating Crucial Factors and Mechanistic Underpinnings. CNS Neurosci. Ther. 2024, 30, e70091. [Google Scholar] [CrossRef] [Scilit]
  209. Pellegrini, C.; Antonioli, L.; Calderone, V.; Colucci, R.; Fornai, M.; Blandizzi, C. Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications? Prog. Neurobiol. 2020, 191, 101806. [Google Scholar] [CrossRef] [Scilit]
  210. Wu, S.; Liu, X.; Jiang, R.; Yan, X.; Ling, Z. Roles and Mechanisms of Gut Microbiota in Patients with Alzheimer’s Disease. Front. Aging Neurosci. 2021, 13, 650047. [Google Scholar] [CrossRef] [Scilit]
  211. Xu, W.; Huang, Y.; Zhou, R. NLRP3 inflammasome in neuroinflammation and central nervous system diseases. Cell Mol Immunol. 2025, 22, 341–355. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  212. Rutsch, A.; Kantsjö, J.B.; Ronchi, F. The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology. Front. Immunol. 2020, 11, 604179. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  213. Shukla, P.K.; Delotterie, D.F.; Xiao, J.; Pierre, J.F.; Rao, R.; McDonald, M.P.; Khan, M.M. Alterations in the Gut-Microbial-Inflammasome-Brain Axis in a Mouse Model of Alzheimer’s Disease. Cells 2021, 10, 779. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  214. Barry, D.J.; Wu, S.S.X.; Cooke, M.B. The Relationship Between Gut Microbiota, Muscle Mass and Physical Function in Older Individuals: A Systematic Review. Nutrients 2024, 17, 81. [Google Scholar] [CrossRef] [Scilit]
  215. Ticinesi, A.; Nouvenne, A.; Cerundolo, N.; Catania, P.; Prati, B.; Tana, C.; Meschi, T. Gut Microbiota, Muscle Mass and Function in Aging: A Focus on Physical Frailty and Sarcopenia. Nutrients 2019, 11, 1633. [Google Scholar] [CrossRef] [Scilit]
  216. Liu, C.; Cheung, W.H.; Li, J.; Chow, S.K.; Yu, J.; Wong, S.H.; Ip, M.; Sung, J.J.Y.; Wong, R.M.Y. Understanding the gut microbiota and sarcopenia: A systematic review. J. Cachexia Sarcopenia Muscle 2021, 12, 1393–1407. [Google Scholar] [CrossRef] [Scilit]
  217. Asaoka, D.; Toda, K.; Yoshimoto, S.; Katsumata, N.; Odamaki, T.; Iwabuchi, N.; Tanaka, M.; Xiao, J.Z.; Nishikawa, Y.; Nomura, O.; et al. Sex-Specific Associations of Gut Microbiota Composition with Sarcopenia Defined by the Asian Working Group for Sarcopenia 2019 Consensus in Older Outpatients: Prospective Cross-Sectional Study in Japan. Nutrients 2025, 17, 1746. [Google Scholar] [CrossRef] [Scilit]
  218. Ticinesi, A.; Lauretani, F.; Milani, C.; Nouvenne, A.; Tana, C.; Del Rio, D.; Maggio, M.; Ventura, M.; Meschi, T. Aging Gut Microbiota at the Cross-Road between Nutrition, Physical Frailty, and Sarcopenia: Is There a Gut-Muscle Axis? Nutrients 2017, 9, 1303. [Google Scholar] [CrossRef] [Scilit]
  219. Mohebali, N.; Weigel, M.; Hain, T.; Sütel, M.; Bull, J.; Kreikemeyer, B.; Breitrück, A. Faecalibacterium prausnitzii, Bacteroides faecis and Roseburia intestinalis attenuate clinical symptoms of experimental colitis by regulating Treg/Th17 cell balance and intestinal barrier integrity. Biomed. Pharmacother. 2023, 167, 115568. [Google Scholar] [CrossRef] [Scilit]
  220. Guo, T.T.; Zhang, Z.; Sun, Y.; Zhu, R.Y.; Wang, F.X.; Ma, L.J.; Jiang, L.; Liu, H.D. Neuroprotective Effects of Sodium Butyrate by Restoring Gut Microbiota and Inhibiting TLR4 Signaling in Mice with MPTP-Induced Parkinson’s Disease. Nutrients 2023, 15, 930. [Google Scholar] [CrossRef] [Scilit]
  221. Tabat, M.W.; Marques, T.M.; Markgren, M.; Löfvendahl, L.; Brummer, R.J.; Wall, R. Acute Effects of Butyrate on Induced Hyperpermeability and Tight Junction Protein Expression in Human Colonic Tissues. Biomolecules 2020, 10, 766. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  222. Liu, T.; Zhang, L.; Joo, D.; Sun, S.-C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2017, 2, 17023. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  223. Huang, C.C.; Tsai, S.F.; Liu, S.C.; Yeh, M.C.; Hung, H.C.; Lee, C.W.; Cheng, C.L.; Hsu, P.L.; Kuo, Y.M. Insulin Mediates Lipopolysaccharide-Induced Inflammatory Responses and Oxidative Stress in BV2 Microglia. J. Inflamm. Res. 2024, 17, 7993–8008. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  224. Chiarini, A.; Gui, L.; Viviani, C.; Armato, U.; Dal Prà, I. NLRP3 Inflammasome’s Activation in Acute and Chronic Brain Diseases-An Update on Pathogenetic Mechanisms and Therapeutic Perspectives with Respect to Other Inflammasomes. Biomedicines 2023, 11, 999. [Google Scholar] [CrossRef] [Scilit]
  225. Grunow, J.J.; Gan, T.; Lewald, H.; Martyn, J.A.J.; Blobner, M.; Schaller, S.J. Insulin signaling in skeletal muscle during inflammation and/or immobilisation. Intensive Care Med. Exp. 2023, 11, 16. [Google Scholar] [CrossRef] [Scilit]
  226. Zhang, Y.; Wang, J.; Wang, X.; Gao, T.; Tian, H.; Zhou, D.; Zhang, L.; Li, G.; Wang, X. The autophagic-lysosomal and ubiquitin proteasome systems are simultaneously activated in the skeletal muscle of gastric cancer patients with cachexia. Am. J. Clin. Nutr. 2020, 111, 570–579. [Google Scholar] [CrossRef] [Scilit]
  227. Ballesteros, J.; Rivas, D.; Duque, G. The Role of the Kynurenine Pathway in the Pathophysiology of Frailty, Sarcopenia, and Osteoporosis. Nutrients 2023, 15, 3132. [Google Scholar] [CrossRef] [Scilit]
  228. Ticinesi, A.; Tana, C.; Nouvenne, A. The intestinal microbiome and its relevance for functionality in older persons. Curr. Opin. Clin. Nutr. Metab. Care 2019, 22, 4–12. [Google Scholar] [CrossRef] [Scilit]
  229. García-Domínguez, M. Pathological and Inflammatory Consequences of Aging. Biomolecules 2025, 15, 404. [Google Scholar] [CrossRef] [Scilit]
  230. Strasser, B.; Ticinesi, A. Intestinal microbiome in normal ageing, frailty and cognition decline. Curr. Opin. Clin. Nutr. Metab. Care 2023, 26, 8–16. [Google Scholar] [CrossRef] [Scilit]
  231. Ticinesi, A.; Nouvenne, A.; Cerundolo, N.; Parise, A.; Mena, P.; Meschi, T. The interaction between Mediterranean diet and intestinal microbiome: Relevance for preventive strategies against frailty in older individuals. Aging Clin. Exp. Res. 2024, 36, 58. [Google Scholar] [CrossRef] [Scilit]
  232. Ghosh, T.S.; Rampelli, S.; Jeffery, I.B.; Santoro, A.; Neto, M.; Capri, M.; Giampieri, E.; Jennings, A.; Candela, M.; Turroni, S.; et al. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: The NU-AGE 1-year dietary intervention across five European countries. Gut 2020, 69, 1218–1228. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  233. Kemmler, W.; Kohl, M.; Fröhlich, M.; Jakob, F.; Engelke, K.; von Stengel, S.; Schoene, D. Effects of High-Intensity Resistance Training on Osteopenia and Sarcopenia Parameters in Older Men with Osteosarcopenia-One-Year Results of the Randomized Controlled Franconian Osteopenia and Sarcopenia Trial (FrOST). J. Bone Miner. Res. 2020, 35, 1634–1644. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  234. Kemmler, W.; Weineck, M.; Kohl, M.; von Stengel, S.; Giessing, J.; Fröhlich, M.; Schoene, D. High Intensity Resistance Exercise Training to Improve Body Composition and Strength in Older Men with Osteosarcopenia. Results of the Randomized Controlled Franconian Osteopenia and Sarcopenia Trial (FrOST). Front. Sports Act. Living 2020, 2, 4. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  235. Kemmler, W.; Kohl, M.; Fröhlich, M.; Engelke, K.; von Stengel, S.; Schoene, D. Effects of High-Intensity Resistance Training on Fitness and Fatness in Older Men with Osteosarcopenia. Front. Physiol. 2020, 11, 1014. [Google Scholar] [CrossRef] [Scilit]
  236. Buskard, A.N.L.; Petrella, R.J. Resistance Training and Weight Loss in Older Adults: A Scoping Review. Sports Med. Open 2023, 9, 67. [Google Scholar] [CrossRef] [Scilit]
  237. Zhang, M.; Song, Y.; Zhu, J.; Ding, P.; Chen, N. Effectiveness of low-load resistance training with blood flow restriction vs. conventional high-intensity resistance training in older people diagnosed with sarcopenia: A randomized controlled trial. Sci. Rep. 2024, 14, 28427. [Google Scholar] [CrossRef] [Scilit]
  238. Coelho-Junior, H.J.; Calvani, R.; Azzolino, D.; Picca, A.; Tosato, M.; Landi, F.; Cesari, M.; Marzetti, E. Protein Intake and Sarcopenia in Older Adults: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health 2022, 19, 8718. [Google Scholar] [CrossRef] [Scilit]
  239. Montiel-Rojas, D.; Nilsson, A.; Santoro, A.; Bazzocchi, A.; de Groot, L.C.P.G.; Feskens, E.J.M.; Berendsen, A.A.M.; Madej, D.; Kaluza, J.; Pietruszka, B.; et al. Fighting Sarcopenia in Ageing European Adults: The Importance of the Amount and Source of Dietary Proteins. Nutrients 2020, 12, 3601. [Google Scholar] [CrossRef] [Scilit]
  240. Coelho-Junior, H.J.; Marzetti, E.; Picca, A.; Cesari, M.; Uchida, M.C.; Calvani, R. Protein Intake and Frailty: A Matter of Quantity, Quality, and Timing. Nutrients 2020, 12, 2915. [Google Scholar] [CrossRef] [Scilit]
  241. Martone, A.M.; Marzetti, E.; Calvani, R.; Picca, A.; Tosato, M.; Santoro, L.; Di Giorgio, A.; Nesci, A.; Sisto, A.; Santoliquido, A.; et al. Exercise and Protein Intake: A Synergistic Approach against Sarcopenia. Biomed. Res. Int. 2017, 2017, 2672435. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  242. Snijders, T.; Verdijk, L.B.; van Loon, L.J. The impact of sarcopenia and exercise training on skeletal muscle satellite cells. Ageing Res. Rev. 2009, 8, 328–338. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  243. Nilwik, R.; Snijders, T.; Leenders, M.; Groen, B.B.; van Kranenburg, J.; Verdijk, L.B.; van Loon, L.J. The decline in skeletal muscle mass with aging is mainly attributed to a reduction in type II muscle fiber size. Exp. Gerontol. 2013, 48, 492–498. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  244. Calvani, R.; Miccheli, A.; Landi, F.; Bossola, M.; Cesari, M.; Leeuwenburgh, C.; Sieber, C.C.; Bernabei, R.; Marzetti, E. Current nutritional recommendations and novel dietary strategies to manage sarcopenia. J. Frailty Aging 2013, 2, 38–53. [Google Scholar] [CrossRef] [Scilit]
  245. Yoshimura, Y.; Matsumoto, A.; Inoue, T.; Okamura, M.; Kuzuya, M. Protein supplementation alone or combined with exercise for sarcopenia and physical frailty: A systematic review and meta-analysis of randomized controlled trials. Arch. Gerontol. Geriatr. 2025, 131, 105783. [Google Scholar] [CrossRef] [Scilit]
  246. Mellen, R.H.; Girotto, O.S.; Marques, E.B.; Laurindo, L.F.; Grippa, P.C.; Mendes, C.G.; Garcia, L.N.H.; Bechara, M.D.; Barbalho, S.M.; Sinatora, R.V.; et al. Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review. Biomedicines 2023, 11, 136. [Google Scholar] [CrossRef] [Scilit]
  247. Yokoyama, Y.; Kitamura, A.; Seino, S.; Kim, H.; Obuchi, S.; Kawai, H.; Hirano, H.; Watanabe, Y.; Motokawa, K.; Narita, M.; et al. Association of nutrient-derived dietary patterns with sarcopenia and its components in community-dwelling older Japanese: A cross-sectional study. Nutr. J. 2021, 20, 7. [Google Scholar] [CrossRef] [Scilit]
  248. Rondanelli, M.; Cereda, E.; Klersy, C.; Faliva, M.A.; Peroni, G.; Nichetti, M.; Gasparri, C.; Iannello, G.; Spadaccini, D.; Infantino, V.; et al. Improving rehabilitation in sarcopenia: A randomized-controlled trial utilizing a muscle-targeted food for special medical purposes. J. Cachexia Sarcopenia Muscle 2020, 11, 1535–1547. [Google Scholar] [CrossRef] [Scilit]
  249. Boirie, Y.; Guillet, C. Fast digestive proteins and sarcopenia of aging. Curr. Opin. Clin. Nutr. Metab. Care 2018, 21, 37–41. [Google Scholar] [CrossRef] [Scilit]
  250. Beaudart, C.; Buckinx, F.; Rabenda, V.; Gillain, S.; Cavalier, E.; Slomian, J.; Petermans, J.; Reginster, J.Y.; Bruyère, O. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: A systematic review and meta-analysis of randomized controlled trials. J. Clin. Endocrinol. Metab. 2014, 99, 4336–4345. [Google Scholar] [CrossRef] [Scilit]
  251. Chang, M.C.; Choo, Y.J. Effects of Whey Protein, Leucine, and Vitamin D Supplementation in Patients with Sarcopenia: A Systematic Review and Meta-Analysis. Nutrients 2023, 15, 521. [Google Scholar] [CrossRef] [Scilit]
  252. Zhang, F.; Li, W. Vitamin D and Sarcopenia in the Senior People: A Review of Mechanisms and Comprehensive Prevention and Treatment Strategies. Ther. Clin. Risk Manag. 2024, 20, 577–595. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  253. Houston, D.K.; Cesari, M.; Ferrucci, L.; Cherubini, A.; Maggio, D.; Bartali, B.; Johnson, M.A.; Schwartz, G.G.; Kritchevsky, S.B. Association between vitamin D status and physical performance: The InCHIANTI study. J. Gerontol. A Biol. Sci. Med. Sci. 2007, 62, 440–446. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  254. Mizuno, T.; Hosoyama, T.; Tomida, M.; Yamamoto, Y.; Nakamichi, Y.; Kato, S.; Kawai-Takaishi, M.; Ishizuka, S.; Nishita, Y.; Tange, C.; et al. Influence of vitamin D on sarcopenia pathophysiology: A longitudinal study in humans and basic research in knockout mice. J. Cachexia Sarcopenia Muscle 2022, 13, 2961–2973. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  255. Aspell, N.; Laird, E.; Healy, M.; Lawlor, B.; O’Sullivan, M. Vitamin D Deficiency Is Associated With Impaired Muscle Strength And Physical Performance In Community-Dwelling Older Adults: Findings From The English Longitudinal Study Of Ageing. Clin. Interv. Aging 2019, 14, 1751–1761. [Google Scholar] [CrossRef] [Scilit]
  256. Shahatah, F.A.; Hill, T.R.; Fairley, A.; Watson, A.W. Ultra-Processed Food Intakes and Health Outcomes in Adults Older Than 60 Years: A Systematic Review. Nutr. Rev. 2025, 83, 1711–1724. [Google Scholar] [CrossRef] [Scilit]
  257. Pagliai, G.; Dinu, M.; Madarena, M.P.; Bonaccio, M.; Iacoviello, L.; Sofi, F. Consumption of ultra-processed foods and health status: A systematic review and meta-analysis. Br. J. Nutr. 2021, 125, 308–318. [Google Scholar] [CrossRef] [Scilit]
  258. Parlak Baskurt, H.; Yardımcı, H. Consumptıon of ultra-processed foods can accelerate age-related appearance of sarcopenıa. Biogerontology 2025, 26, 112. [Google Scholar] [CrossRef] [Scilit]
  259. Martínez-Arnau, F.M.; Fonfría-Vivas, R.; Buigues, C.; Castillo, Y.; Molina, P.; Hoogland, A.J.; van Doesburg, F.; Pruimboom, L.; Fernández-Garrido, J.; Cauli, O. Effects of Leucine Administration in Sarcopenia: A Randomized and Placebo-controlled Clinical Trial. Nutrients 2020, 12, 932. [Google Scholar] [CrossRef] [Scilit]
  260. Abe, S.; Ezaki, O.; Suzuki, M. Medium-Chain Triglycerides in Combination with Leucine and Vitamin D Increase Muscle Strength and Function in Frail Elderly Adults in a Randomized Controlled Trial. J. Nutr. 2016, 146, 1017–1026. [Google Scholar] [CrossRef] [Scilit]
  261. Tieland, M.; Trouwborst, I.; Clark, B.C. Skeletal muscle performance and ageing. J. Cachexia Sarcopenia Muscle 2018, 9, 3–19. [Google Scholar] [CrossRef] [Scilit]
  262. Bukhari, S.S.; Phillips, B.E.; Wilkinson, D.J.; Limb, M.C.; Rankin, D.; Mitchell, W.K.; Kobayashi, H.; Greenhaff, P.L.; Smith, K.; Atherton, P.J. Intake of low-dose leucine-rich essential amino acids stimulates muscle anabolism equivalently to bolus whey protein in older women at rest and after exercise. Am. J. Physiol. Endocrinol. Metab. 2015, 308, E1056–E1065. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  263. Rondanelli, M.; Klersy, C.; Terracol, G.; Talluri, J.; Maugeri, R.; Guido, D.; Faliva, M.A.; Solerte, B.S.; Fioravanti, M.; Lukaski, H.; et al. Whey protein, amino acids, and vitamin D supplementation with physical activity increases fat-free mass and strength, functionality, and quality of life and decreases inflammation in sarcopenic elderly. Am. J. Clin. Nutr. 2016, 103, 830–840. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  264. Bo, Y.; Liu, C.; Ji, Z.; Yang, R.; An, Q.; Zhang, X.; You, J.; Duan, D.; Sun, Y.; Zhu, Y.; et al. A high whey protein, vitamin D and E supplement preserves muscle mass, strength, and quality of life in sarcopenic older adults: A double-blind randomized controlled trial. Clin. Nutr. 2019, 38, 159–164. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  265. Roager, H.M.; Vogt, J.K.; Kristensen, M.; Hansen, L.B.S.; Ibrügger, S.; Mærkedahl, R.B.; Bahl, M.I.; Lind, M.V.; Nielsen, R.L.; Frøkiær, H.; et al. Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: A randomised cross-over trial. Gut 2019, 68, 83–93. [Google Scholar] [CrossRef] [Scilit]
  266. Yuan, C. Molecular mechanisms and therapeutic strategies of gut microbiota modulation in Sarcopenia (Review). Oncol. Lett. 2025, 29, 104. [Google Scholar] [CrossRef] [Scilit]
  267. Rooks, D.S.; Laurent, D.; Praestgaard, J.; Rasmussen, S.; Bartlett, M.; Tankó, L.B. Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy. J. Cachexia Sarcopenia Muscle 2017, 8, 727–734. [Google Scholar] [CrossRef] [Scilit]
  268. Rooks, D.; Petricoul, O.; Praestgaard, J.; Bartlett, M.; Laurent, D.; Roubenoff, R. Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort. J. Cachexia Sarcopenia Muscle 2020, 11, 1525–1534. [Google Scholar] [CrossRef] [Scilit]
  269. Rooks, D.; Praestgaard, J.; Hariry, S.; Laurent, D.; Petricoul, O.; Perry, R.G.; Lach-Trifilieff, E.; Roubenoff, R. Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study. J. Am. Geriatr. Soc. 2017, 65, 1988–1995. [Google Scholar] [CrossRef] [Scilit]
  270. Rooks, D.; Swan, T.; Goswami, B.; Filosa, L.A.; Bunte, O.; Panchaud, N.; Coleman, L.A.; Miller, R.R.; Garcia Garayoa, E.; Praestgaard, J.; et al. Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial. JAMA Netw. Open 2020, 3, e2020836. [Google Scholar] [CrossRef] [Scilit]
  271. Rondanelli, M.; Gasparri, C.; Cavioni, A.; Sivieri, C.; Barrile, G.C.; Mansueto, F.; Perna, S. A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial. Nutrients 2024, 16, 1369. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  272. Cruz-Jentoft, A.J. Beta-Hydroxy-Beta-Methyl Butyrate (HMB): From Experimental Data to Clinical Evidence in Sarcopenia. Curr. Protein Pept. Sci. 2018, 19, 668–672. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  273. Rossi, A.P.; D’Introno, A.; Rubele, S.; Caliari, C.; Gattazzo, S.; Zoico, E.; Mazzali, G.; Fantin, F.; Zamboni, M. The Potential of β-Hydroxy-β-Methylbutyrate as a New Strategy for the Management of Sarcopenia and Sarcopenic Obesity. Drugs Aging 2017, 34, 833–840. [Google Scholar] [CrossRef] [Scilit]
  274. Phillips, S.M.; Lau, K.J.; D’Souza, A.C.; Nunes, E.A. An umbrella review of systematic reviews of β-hydroxy-β-methyl butyrate supplementation in ageing and clinical practice. J. Cachexia Sarcopenia Muscle 2022, 13, 2265–2275. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  275. Roschel, H.; Hayashi, A.P.; Fernandes, A.L.; Jambassi-Filho, J.C.; Hevia-Larraín, V.; de Capitani, M.; Santana, D.A.; Gonçalves, L.S.; de Sá-Pinto, A.L.; Lima, F.R.; et al. Supplement-based nutritional strategies to tackle frailty: A multifactorial, double-blind, randomized placebo-controlled trial. Clin. Nutr. 2021, 40, 4849–4858. [Google Scholar] [CrossRef] [Scilit]
  276. Jyväkorpi, S.K.; Ramel, A.; Strandberg, T.E.; Piotrowicz, K.; Błaszczyk-Bębenek, E.; Urtamo, A.; Rempe, H.M.; Geirsdóttir, Ó.; Vágnerová, T.; Billot, M.; et al. The sarcopenia and physical frailty in older people: Multi-component treatment strategies (SPRINTT) project: Description and feasibility of a nutrition intervention in community-dwelling older Europeans. Eur. Geriatr. Med. 2021, 12, 303–312. [Google Scholar] [CrossRef] [Scilit]
  277. Vikberg, S.; Sörlén, N.; Brandén, L.; Johansson, J.; Nordström, A.; Hult, A.; Nordström, P. Effects of Resistance Training on Functional Strength and Muscle Mass in 70-Year-Old Individuals with Pre-sarcopenia: A Randomized Controlled Trial. J. Am. Med. Dir. Assoc. 2019, 20, 28–34. [Google Scholar] [CrossRef] [Scilit]
  278. Li, Z.; Cui, M.; Yu, K.; Zhang, X.W.; Li, C.W.; Nie, X.D.; Wang, F. Effects of nutrition supplementation and physical exercise on muscle mass, muscle strength and fat mass among sarcopenic elderly: A randomized controlled trial. Appl. Physiol. Nutr. Metab. 2021, 46, 494–500. [Google Scholar] [CrossRef] [Scilit]
  279. Hsu, K.J.; Liao, C.D.; Tsai, M.W.; Chen, C.N. Effects of Exercise and Nutritional Intervention on Body Composition, Metabolic Health, and Physical Performance in Adults with Sarcopenic Obesity: A Meta-Analysis. Nutrients 2019, 11, 2163. [Google Scholar] [CrossRef] [Scilit]
  280. Lin, C.C.; Shih, M.H.; Chen, C.D.; Yeh, S.L. Effects of adequate dietary protein with whey protein, leucine, and vitamin D supplementation on sarcopenia in older adults: An open-label, parallel-group study. Clin. Nutr. 2021, 40, 1323–1329. [Google Scholar] [CrossRef] [Scilit]
  281. Bauer, J.M.; Verlaan, S.; Bautmans, I.; Brandt, K.; Donini, L.M.; Maggio, M.; McMurdo, M.E.; Mets, T.; Seal, C.; Wijers, S.L.; et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: A randomized, double-blind, placebo-controlled trial. J. Am. Med. Dir. Assoc. 2015, 16, 740–747. [Google Scholar] [CrossRef] [Scilit]
  282. Andreo-López, M.C.; Contreras-Bolívar, V.; García-Fontana, B.; García-Fontana, C.; Muñoz-Torres, M. The Influence of the Mediterranean Dietary Pattern on Osteoporosis and Sarcopenia. Nutrients 2023, 15, 3224. [Google Scholar] [CrossRef] [Scilit]
  283. Dominguez, L.J.; Veronese, N.; Smith, L.; Ragusa, F.S.; Schirò, P.; Di Bella, G.; Barbagallo, M. Associations Between Adherence to the Mediterranean Diet and Incident Sarcopenia in Prospective Cohort Studies. Nutrients 2025, 17, 313. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.